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CHAPTER I
INTRODUCTION
Enveloped Virus Entry.
Enveloped viruses are produced coated in a lipid membrane. Thus, enveloped
virus-cell entry requires fusion of viral and host cell membranes. Numerous glycoproteins
extending from the viral membrane catalyze this fusion reaction. These fusion
glycoproteins store energy upon folding in the producer cell [reviewed in [1]] . This
energy is held through internal interactions [2] or by associated viral proteins [3]. This
stored energy is released upon unfolding and refolding of the glycoprotein and provides
the force necessary to overcome the energy barrier for membrane fusion [4]. The
structural transformations that the glycoproteins undergo upon triggering are unstable and
tend towards a lower energy state, releasing the energy required for membrane fusion [2,
5]. Therefore, once the “trigger” of a fusion glycoprotein is pulled, and its stored energy
released, it will rapidly become inactive [6]. It is necessary that these glycoproteins
remain catalytically-inactive on extracellular virus particles and only become triggered to
unfold in an environment that is ideal for successful membrane fusion and infection. To
increase the odds of successful infection, enveloped viruses have developed strategies to
undergo the fusion reaction only in response to cellular and environmental factors.
Fusion glycoprotein triggering factors include host cell receptors, endosomal
acids, and proteases. Many viruses require a single, soluble trigger, for example,
influenza A virus (IAV) fusion proteins are triggered by protons within the target-cell
1
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endosome [7]. Other viruses require two triggering agents, for example, ASLV
fusion proteins are partially advanced into fusion-catalyzing forms by host cell receptor
binding [8], and then fully execute fusion after being exposed to endosomal protons [9].
Although there is a large variety in the structure and mechanisms of fusion
glycoproteins, the membrane fusion process has many common features. When fusion
glycoproteins are in their folded, “loaded” conformation they bury hydrophobic domains
called fusion peptides [10]. Upon triggering, the fusion glycoprotein will undergo
structural transitions that extend this fusion peptide towards the target membrane. Due to
its hydrophobicity, the fusion peptide will insert into the hydrophobic region of the cell’s
lipid bilayer. Further structural transitions bring the viral and cellular membranes into
close proximity. After being brought into contact, the outer leaflets will meld. This state,
where only one leaflet of each membrane is joined but there is no pore is called
hemifusion [4, 11, 12]. Hemifusion is relatively stable [13], but is not sufficient for
infection. For successful infection, the virus must form a fusion pore through further
structural transitions. It is likely that most if not all enveloped viruses require the
simultaneous refolding of multiple fusion glycoproteins to overcome the membrane
fusion energy barrier and form the fusion pore [13]. Once the fusion pore forms, it
expands due to favorable energetics [9, 12], releasing the genetic and protein contents of
the virion into the cytoplasm.

Coronaviruses.
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Coronaviruses (CoVs) are enveloped, positive-sense RNA viruses in the order
Nidovirales. The single-stranded genome is the largest amongst RNA viruses at a length
of up to 32 kb. The family Coronaviridae is divided into 4 genera based on sequence
similarity: Alpha-, Beta-, Gamma-, and Deltacoronaviruses. Coronaviruses were first
isolated in chickens in 1931 [14] and subsequently isolated as pathogens of mammals
including swine [15] and mice [16]. In 1967, the first human CoVs, human coronavirus
229E (HCoV-229E) and human coronavirus OC43 (HCoV-OC43) were identified from
upper respiratory tract samples taken a year earlier [17]. This study was the first to
characterize coronaviruses as a viral family based on the morphology of the virions when
observed by electron microscopy. Since then, other CoVs from the alpha- and betagenera have been isolated from humans. However, until 2002, human CoVs were
thought to cause only mild respiratory infections and posed no threat to global health [18,
19]. Recent outbreaks of zoonotic-origin CoVs have led to a greater interest in the threat
of CoV pandemics.
Coronaviruses as threats to global health. The two most notable human CoV
pathogens are the Severe Acute Respiratory Syndrome (SARS)-CoV and Middle East
Respiratory Syndrome (MERS)-CoV which have caused pandemics in recent years. The
SARS epidemic started in November 2002 in the Guangdong province of southern China.
From there, it spread to the more populated Hong Kong, where it exhibited somewhat
efficient human-to-human transmission. The virulence and transmissibility of the SARSCoV led to fears of a possible global pandemic. Before transmission was stopped using
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effective epidemiologic techniques [20], SARS infected 8,096 people and caused 774
deaths [WHO, SARS report].
The MERS epidemic started in Saudi Arabia in 2012 [21] and has since spread to
multiple countries throughout the Middle East and the world, most notably causing a
large outbreak in South Korea in 2015. As of December 2016, MERS-CoV has infected
1,841 people with 652 reported fatalities [WHO, MERS report]. While MERS-CoV
causes a severe respiratory disease like SARS-CoV, many patients succumbed to renal
failure [21, 22] and MERS-CoV has been shown to infect kidney cells [23]. As of this
writing, MERS is still circulating in populations in the Middle East.
Zoonotic transmission of coronaviruses. Most, if not all, human CoVs likely
originated as viruses circulating in animal populations. The alphacoronavirus HCoV229E likely had a bat coronavirus as an ancestor before spreading into humans around
200 years ago [24]. The betacoronavirus HCoV-OC43, which causes mild respiratory
illness in humans, shares sequence similarity with bovine coronavirus (BCoV) and a
molecular clock analysis of the HCoV-OC43 S protein suggests the virus spread from
cows into human about 120 years ago [25]. Interestingly, both pandemic CoVs likely
originated in bats before transmitting to an intermediate host and eventually to humans
[26-28]. The ability to move between species likely contributes to the dangers posed by
pandemic-potential CoVs. This is in line with many other zoonotic diseases that have
recently posed threats to global health including influenza A [29], Ebola virus [30], zika
virus [31], and several alphaviruses [32].
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The SARS-CoV originated in Chinese horseshoe bats [33] which can likely
harbor multiple SARS-like coronaviruses without adverse effects [34]. The virus then
moved to small mammals, such as palm civet cats, which were held in close proximity in
Chinese markets. Interestingly, the S protein of these viruses were capable of binding to
bat, civet, and human ACE2. This diversity of receptor utilization facilitated SARS
transmission to humans and the beginning of the SARS epidemic.
MERS-CoV, like SARS, also likely started in bats [27], moved to an intermediate
host [35], and then transmitted to humans. The closest, sequenced relative to MERSCoV are the bat viruses HKU4 and HKU5 [27, 28]. Furthermore, an RNA fragment of
the RNA-dependent RNA polymerase identical to MERS-CoV was isolated in both an
Egyptian Tomb bat and several dromedary camels in Saudi Arabia [36]. These data,
along with the discovery of MERS-neutralizing antibodies in camel populations [37],
suggest that a MERS-like virus moved from bat populations into camels and then into
humans who were in close contact. MERS S proteins can bind to both human and bat
versions of the DPP4 receptor and the DPP4 gene from several bats shows evidence of
adaptive evolution [38]. This suggests that MERS-like viruses may have spread in bat
populations for some time and are pathogenic enough to exert a selective pressure on bat
DPP4 genes. There is no study that determines if camel DPP4 genes have evolved in a
similar manner in the presence of MERS-like CoV infections. These studies suggest that
pathogenic, MERS-like viruses have been circulating in bats for some time and have only
recently transmitted to camels and humans.
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It is unclear why long-circulating MERS-like bat CoVs have only recently spread
to new hosts. Identifying host factors that facilitate CoV infections may provide an
explanation. A partial explanation for the effective transmission of CoVs between host
species is the relative flexibility of CoV entry routes, which expands the available entry
factors a given zoonotic CoV may utilize. This dissertation focuses on the multiple
cellular factors that contribute to CoV entry into host cells. Unlike many enveloped
viruses, where membrane fusion occurs at a single, well-defined location, CoVs can
participate in entry at multiple locations in the target cell. Recent studies, including our
own, have uncovered the subcellular location of these entry events and have
characterized both the viral and host-cell factors that determine which route a CoV is
likely to take.

Coronavirus Entry.
Coronavirus entry relies on membrane fusion catalyzed by the Spike (S)
glycoprotein [39]. The S protein is a class I fusion glycoprotein like the influenza
hemagglutinin (HA), human immunodeficiency virus (HIV) gp41, and ebolavirus GP.
Trimeric class I fusion glycoproteins are characterized by their helical fusion domains [1,
6, 40]. Upon a triggering event, these helices extend towards the target membrane and
embed the fusion peptide. This structure, called the “extended intermediate” [2], was
once thought to be unstable but more recent studies of influenza HA [2] and HIV gp41
[41] suggest these structures can exist on the order of minutes, if not indefinitely. In
order to complete the fusion process, the fusion intermediate must collapse to bring the
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fusion peptide and the viral membrane into close proximity. This process is facilitated by
the strong interaction of two helical heptad repeat (HR) regions within the fusion protein
[6, 8, 11, 42, 43]. The affinity for these two domains for each other leads to a
“zippering” of the extended intermediate onto itself leading to their direct interaction [6,
44]. This process brings together the two membranes and fuses the outer leaflet of each,
causing hemifusion. Completion of this rearrangement connects the two HRs of each
trimer and forms the final structure called a “six-helix bundle” [44, 45]. The formation of
the remarkably thermally stable six-helix bundle coincides with pore formation and it is
likely that pore formation requires fusion proteins to form a six-helix bundle. Studies
using influenza suggest that 3-6 adjacent glycoproteins must participate in fold-back to
provide enough energy for pore formation and six-helix bundle formation [2].
While CoV S proteins share the basic structure and function of other class-I viral
fusion proteins, they also have some unique features. CoV S proteins are composed of
the S1 domain, which is responsible for receptor binding [46], and the S2 domain, which
carries out the fusion reaction [39]. The S1 domain is separated into two further
domains, the N-terminal domain (NTD) and the C-terminal domain (CTD), which can
participate in binding to target cells using various cellular factors. Generally, the NTD
region binds to sugar moieties on target cells [47-50] while the CTD binds proteinaceous
receptors [51-53]. Only the NTD of MHV is unique in that it appears to have evolved
from binding sugars to binding the protein carcinoembryonic antigen-related adhesion
molecule 1 (CEACAM) [54]. The S1 domain also acts as a shield of S2 and keeps the
fusion machinery locked in place and free from immune detection (Figure 2) [55].
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In order for CoV S proteins to complete fusion, the S1 domain must be shed from
the S2 following receptor binding. This process is facilitated by cleavage events that
occur at two cleavage sites, the S1/S2 and the S2’. These sites are unstructured regions
of the S [56] that generally contain arginine-serine (R/S) sequences that act as targets for
cleavage by serine proteases [57-60] and likely contain as-yet unidentified substrates for
cysteine proteases [61-63].
A defined cleavage site exists at the interface of the S1 and S2 domains. This
S1/S2 cleavage site is exposed in native viruses. Therefore, the site can be cleaved in
producer cells [59], in the extracellular space [64], or on target cells following receptor
binding. The cleavage at S1/S2 does not remove the S1 domain, as it must remain
associated through non-covalent bonds to S2 to facilitate receptor binding, but it allows
for more flexibility in the S trimer and primes the virus for the triggering cleavage [65].
While cleavage at S1/S2 does not appear to be strictly required for successful fusion, the
extent to which S1/S2 is cleaved drastically affects CoV entry routes (see “Viral
Determinants of Entry Routes”).
While direct experimental evidence is lacking, cleavage at the S2’ site is thought
to be the triggering mechanism for CoV fusion [57, 59]. In the native state, the S2’
region exists in an alpha-helix on the surface of the S2. Receptor binding causes
structural changes to S2 that cause the S2’ region to become unstructured and available to
cellular proteases [56]. Therefore, proteolytic cleavage of S2’occurs only on receptorbound viral S (Figure 1) [65, 66]. Cleavage at S2’ is presumed to release stored energy,
extend the HR regions, and insert the fusion peptide into the target membrane forming
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the extended intermediate. Like other class I viral fusion peptides, the extended
intermediate zippers to bring the HR1 and HR2 regions together, ultimately leading to the
formation of the six-helix bundle [43, 67, 68] and the fusion pore. Likely, as with
influenza A virus, fusion occurs only after triggering of multiple adjacent S proteins.
While there are no FDA approved inhibitors of CoV entry, there are several
known mechanisms for blocking S-mediated entry. Antibodies can be generated by
humoral immune responses and generally bind to S1and prevent CoV binding to cells
[69]. While these antibodies are effective in preventing infection, they can drive
evolution of escape mutants. Antibodies to the fusion machinery are rare due to burying
of these domains in the internal glycoprotein structure. Protease inhibitors can prevent
cleavage of S2’ by cellular proteases and can be effective in blocking CoV infections in
cell culture [70-73]. Furthermore, a recent study using a mouse model of SARS
demonstrated that serine protease inhibitors prevent spread of the virus in mice [74]. A
broad range of inhibitors may be necessary to prevent infection, due to the flexibility of
CoV entry routes (discussed below), which may limit the usefulness of these drugs in
clinical settings. Additionally, small peptides corresponding to the HR2 region of the S
(Figure 1) can prevent entry by preventing the pore that follows triggering. These
peptides take advantage of the strong affinity between HR1 and HR2. HR2 peptides bind
to HR1 while the spike is in the extended intermediate conformation. This binding
sterically blocks intramolecular HR1 and HR2 interactions and, thus, prevents complete S
zippering and six-helix bundle formation [75]. These peptides have limited efficacy
because extended S trimers exist for a short time and may only be present in the
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endosomal compartment during late entry (Figure 3). Furthermore, as seen with blocking
antibodies, HR2 peptide escape mutants have been characterized in MHV [76]. Thus,
while there are many potential mechanisms for preventing CoV fusion and infection,
none have proven broadly effective.
Entry routes: early vs. late. Generally, enveloped virus fusion occurs at a
specific subcellular location in target cells. CoVs, however, show a unique flexibility in
the location of the fusion event. CoVs can fuse at the cell surface, in what is called “early
entry” [65, 70, 77-79], or in the late endocytic compartment, in what is termed “late
entry” [63, 71, 80, 81]. The central principle of CoV entry is that the subcellular location
of a sufficient number of S2’ cleavages determines which route the virus ultimately uses
(Figure 3). Understanding this tenet, we can examine CoV entry based on the cleavage
state of CoV S proteins at specific subcellular locations.
Early entry occurs at the cell surface or very soon after endocytosis. Viruses that
enter early are cleaved at S2’ by cell-surface transmembrane serine proteases (TTSPs)
[70, 73, 77, 79, 82, 83] or proprotein convertases [59]. Thus, early entry is susceptible to
inhibition by serine protease inhibitors such as camostat and leupeptin. CoV early entry
is completely resistant to cysteine protease inhibitors (which inhibit cathepsins) and
alteration of the pH in target endosomes. In early entry, fusion can occur at the cell
surface [84] in the amount of time it takes for transmembrane proteases to cleave S
substrates. This results in a very rapid delivery of the viral genome into the cytoplasm of
the cell. Viruses that enter early may bypass innate immune sensors or antiviral effectors
that are found in the endosomal compartment [77, 79].
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Figure 1. The coronavirus fusion reaction. The structural transitions of CoV S proteins are
illustrated proceeding from receptor binding on the left to successful fusion on the right. S1 binds
to a receptor on the target cells which induces a conformational in the S, exposing cleavage sites
between S1 and S2. Cellular proteases (scissors) then cleave S1 away from the fusion machinery
contained in S2. The fusion peptide (FP) inserts into the target membrane anchoring the virus
and cell together. The heptad repeat 2 (HR2) then zippers up to interact with the heptad repeat 1
(HR1) bringing the membranes together. The successful refolding of enough adjacent S2s leads
to fusion of viral and cell membranes and release of the viral genome into the target cell. Figure
adapted from Jung-Eun Park.
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Figure 2. Coronavirus Spike structure and cleavage sites. (A) The coronavirus S trimer is
depicted in a native (left) and receptor bound conformation with one monomer removed for
clarity (right). The S1 domain, represented by the globular head of the S protein, is divided into
two regions the N-terminal domain (NTD, orange) and C-terminal domain (CTD, blue). The
S1/S2 cleavage site (S1/S2 CS) is shown in its uncleaved, native state and resides in an
unstructured region between S1 and S2. The S2’ cleavage site (S2’ CS) is exposed only after
receptor binding and is immediately N-terminal to the fusion peptide (red triangle). The amino
acid sequences of S1/S2 and S2’ CS of various CoVs are listed below. (B) Close-up view of
receptor-bound S shows folded conformation of S1 structure before S2’ cleavage. The black oval
denotes region of the HR1 thought to participate in intramolecular interactions while the red oval
indicates the region of the HR1 that interacts with the CTD. Figure adapted from Dr. Jung-Eun
Park.
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Late entry occurs in the late endosome or lysosomal compartment. Late entry is
dependent on cathepsin-mediated cleavage of S2’ leading to S2 triggering [57, 61, 63, 71,
73, 80, 81, 85, 86]. Therefore, late entry is indirectly dependent on pH, as a low pH is
required for activation of cathepsins [87]. Furthermore, late entry is inhibited by cysteine
protease inhibitors such as E64D [65]. Late entry takes a much longer time than entry at
the cell surface due to delayed activation of CoV S proteins by endosomal proteases.
Indeed, viruses may take more than an hour to successfully fuse when dependent on late
entry [85]. While viruses that enter late have a longer time span with which to
successfully fuse, they may be exposed to the harsh environment of the lysosomal
compartment and encounter a larger amount of innate immune sensors before they
complete the entry process. Indeed, over-proteolysis of MERS S proteins leads to nonfunctional fragments which are incapable of infection [65, 82]. Perhaps because of this,
late entry is less efficient than early entry in many in vitro [65, 73, 79] and in vivo [74]
settings.
Viral determinants of entry routes. S2’ cleavage. As mentioned above, the S2’
cleavage site contains arginine-serine (R/S) sequences that act as targets for serine
proteases. Most CoV S proteins contain only a single arginine (R/S) at the S2’ site (See
Figure 2A), which acts as a somewhat inefficient substrate for PCs and TTSPs at the cell
surface. However, some CoV S proteins (e.g., MERS-CoV and infectious bronchitis
virus strain [IBV] Beaudette) have multiple arginines arranged in an RxxR/S motif (See
Figure 2A). The RxxR/S motif is a classical substrate for proprotein convertases such as
furins. Therefore, the S proteins
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Figure 3. Model of CoV Entry Routes. CoVs enter cells through the cell surface “early” entry
route or endosomal “late” entry route depending on which proteases activate the Spike proteins.
Early entry depends on complexes of receptors and transmembrane proteases held together by
tetraspanin scaffolding proteins. Early entry occurs at or near the cell surface and occurs
relatively rapidly. If a CoV S is unable to be cleaved by transmembrane proteases, due to S
sequence or target cell protease expression, the virus must undergo endocytosis and be activated
by cathepsins in the late endosome/lysosome. This late entry is slower, likely due to the time
necessary to cleave a sufficient number of S proteins.
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containing RxxR/S motifs have an expanded range of host cell proteases available for S
activation [59, 88]. This expanded range is evidenced by the fact that these viruses
become significantly resistant to cathepsin inhibitors and bafilomycin A treatment[59, 65,
73].
Reverse genetics experiments have further emphasized the role of the S2’
cleavage site in determining entry routes. For example, introducing furin substrate
sequences in the S2’ site of SARS-CoV, MHV, and PEDV S proteins renders these
viruses independent of endosomal cathepsins [58, 80, 84] and more likely to undergo
early entry. Furthermore, mutating the RxxR/S motif to SxxG/S renders MERS entry
completely dependent on cathepsins and independent of TTSPs (observed by Jung-Eun
Park). These results also confirm that there is an as-yet unknown cathepsin cleavage site
near the fusion peptide can also act as a triggering target.
S1/S2 cleavage. The S1/S2 cleavage site plays a role in entry route determination
in part by determining the stability of the S proteins upon interaction with target cells.
Because the S1/S2 site is exposed on native viruses [56], cleavage of S1/S2 can occur in
producer cells [59], in the extracellular space [64], or on target cells following receptor
binding [70, 89]. The cleavage state of S1/S2 upon encountering a target cell influences
the entry route by determining the likelihood of S2’ cleavage at the surface or in the
endosome. A CoV with a cleaved S1/S2 will be less stable and will more efficiently
transition to a state in which the S2’ site is exposed [65]. Conversely, a virus with an
uncleaved S1/S2 will remain rigid and will either require a higher concentration/specific
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activity of target cell proteases to perform the S2’ triggering cleavage or would need
some other stimulus to destabilize the S and expose the S2’ site.
Many CoV S proteins contain a furin substrate sequence at S1/S2 cleavage site
(See Figure 2A), thereby S1/S2 cleavage is mostly carried out by furin and related
proprotein convertases in the exocytic pathway of virus producer cells [90]. This is the
case for most MHV strains, which can participate in both early and late entry events. By
contrast, the MHV strain 2 (MHV-2) S lacks this furin substrate site and is secreted from
producer cells in an uncleaved state [91]. MHV-2 entry is strikingly more sensitive to
inhibitors of endosomal cathepsins [63], which suggests that MHV-2 enters cells late.
These data support the conclusions of Park et al. that a change in the S1/S2 sequence can
determine the entry route of related viruses.
Like MHV-2, SARS-CoV is produced with an uncleaved S protein. However,
studies indicate that SARS-CoV S proteins can be proteolyzed by extracellular proteases
such as trypsin and elastase [64]. Cleaving SARS S by these extracellular proteases or
reverse genetics inclusion of furin substrate sequences at S1/S2 cleavage site facilitated
SARS-CoV entry in target cells, including lung like epithelial cells [57, 65]. These data
suggest that the efficiency of serine protease cleavage of S1/S2 can affect CoV cell
tropism.
Recent experiments with MERS-CoV have reinforced the importance of S1/S2 on
cell tropism and infection. Like MHV, the MERS S protein contains a furin substrate site
at S1/S2 and is cleaved in producer cells [65, 92]. S1/S2 cleavage renders MERS viruses
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capable of infecting cells through both early and late entry pathways. However, removal
of furin-mediated S1/S2 cleavage sites limits virus entry to only those cells that contain
sufficient amounts of endosomal proteases and renders the viruses unresponsive to TTSP
expression[65]. This is important, because the lung cell types known to be infected by
MERS-CoV have relatively low expression of the priming cathepsin L [65, 73, 93].
These data suggest that the relative stability of S proteins upon encountering target cells
is an important determinant of CoV entry routes.
S1 domain. The S2’ cleavage site can only be exposed following receptor
binding by and shedding of the S1 domain [65, 94, 95]. Importantly, many residues in S1
domain form interactions with S2 domain, which stabilize the S proteins and prevent
abortive activation of the fusion reaction. A recent structural study of a human
coronavirus HKU1 S protein highlighted the interaction between residues in the HR1 and
the S1 domain in the pre-fusion structure (Figure 2B) [56]. Mutations of these residues
could potentially lead to destabilization of the S protein and increased utilization of early
entry routes.
A recent study may provide insights into the possibility of S stabilizing
interactions determining viral entry routes. Several amino acid differences were
identified in the S1 domain of HCoV-229E clinical isolates compared to a cell-culture
adapted lab strain [79]. Two of these mutations (R642M and N714K) correlated with a
decreased reliance on cathepsin proteases and an increased utilization of TMPRSS2 in
vitro. Furthermore, upon passage in TTSP-poor cells the viruses gained a second site
mutation (I577S) to reacquire the ability to utilize cathepsins. The nature of this
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mutation, from a nonpolar to a polar amino acid, suggests that intramolecular interactions
may play a role in determining protease utilization. Interestingly, all of these mutations
occurred in the CTD which is thought to participate in many stabilizing intramolecular
interactions.
Cellular determinants of entry routes. Recent studies indicate that early entry of CoVs
requires coordination of several cellular proteins at the cell surface [96]. CoV S proteins
must be cleaved by transmembrane proteases while attached to a receptor in order to
successfully complete the fusion reaction [65, 94, 95]. Furthermore, it is likely that many
adjacent S proteins must be cleaved for fusion pore formation, as seen with other class I
viruses [2]. This means that cellular receptors and activating proteases must reside in
close proximity on the cell surface and with a high enough concentration/activity to
trigger multiple adjacent S proteins. Thus, early entry is dependent on the close
proximity and concentration of receptors and transmembrane proteases. Unlike
membrane-anchored TTSPs, cathepsins are soluble proteases. Thus, activating cleavage
of S proteins by cathepsins is dependent mainly on their concentration/specific activity
instead of their precise localization.
CoV receptors. The first step in CoV entry is virion attachment to target cells.
CoVs can attach to a diverse array of transmembrane anchored molecules. While some
CoVs, such as the Betacoronavirus HCoV-OC43 and the Gammacoronavirus infectious
bronchitis virus (IBV), bind to sugar moieties on membrane proteins [97, 98], the
majority of CoVs bind proteinaceous receptors. Indeed, receptors are the primary
determinant of target cell susceptibility to a CoV. While there is no evidence that
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receptors directly determine CoV entry routes, it is also apparent that CoVs utilize
specific proteinaceous receptors for reasons that go beyond simply binding to cells.
Indeed, there are interesting findings that suggest that CoVs evolve to use receptors that
can facilitate early entry.
There appears to be little structural conservation among CoV receptors and even
related CoVs can use drastically different receptors. For example, the Betacoronaviruses
SARS and MERS use the zinc peptidase angiotensin converting enzyme 2 (ACE2) [99]
and the unrelated serine peptidase dipeptidyl peptidase 4 (DPP4) [100] as receptors,
respectively. Conversely, distantly related CoVs have convergently evolved to use the
same receptor. The Alphacoronavirus HCoV-NL63, which is phylogenetically distant
from SARS-CoV, uses ACE2 [101] as a receptor. Furthermore, HCoV-NL63 binds at a
different domain of ACE2 than SARS, which suggests convergent evolution of the two
viruses as opposed to a shared ancestry [102].
The diversity of CoV receptor usage along with evidence of convergent evolution
suggests that the viruses select receptors based on common properties. One common
theme is that, with the exception of the MHV receptor CEACAM, all the CoV receptors
(ACE2, DPP4 and aminopeptidase N [APN]) are peptidases. Interestingly, the catalytic
activity of these peptidases is dispensable for CoV entry in all cases [99, 100, 103].
Thus, there is a property of these receptors that is important for CoV entry that is distinct
from their peptidase function.
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The subcellular locations of transmembrane peptidases are thought to be tightly
regulated [104], as mislocalization can lead to a number of disorders [105]. Thus, it is
likely that cell-surface peptidases are held in protease-rich regions of the cell that could
facilitate close interaction of the receptor and an activating protease. Indeed, multiple
CoV receptors have been shown to interact with tetraspanin partner proteins (discussed
below) along with transmembrane serine proteases [96]. Thus, the driving factor for CoV
utilization of receptors may be their ability to form complexes with scaffolding proteins
and priming proteases.
Cellular Proteases. Producer and target cell proteases are the most important
factor in determining the route of CoV entry. As discussed above, host proteases can
cleave CoV S proteins in producer cells, in the extracellular space, and/or on the target
cell. The abundance and identity of the different proteases present in producer cells and
target cells can influence the entry route of an incoming CoV.
Cleavage of the S1/S2 site can occur in the producer cells during transit of nascent
virions through the trans-Golgi network [57, 59]. These cleavages are performed largely
by proprotein convertases, especially furin. These proteases cleave at the S1/S2 interface
of the S protein (Figure 2) and generally destabilize the S. As discussed above, this
destabilization is thought to facilitate early entry events [57, 65], likely by more rapidly
exposing the S2’ cleavage sites to target cell transmembrane proteases. MERS viruses
produced in cells that lack furin activity enter target cells less efficiently and with a
greater dependence on cathepsins [65]. Thus, furin activity in producer cells correlates
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with CoV early entry. Interestingly, proprotein convertases can also cleave incoming
CoV S proteins and may be potent facilitators of early entry [59].
The most important classes of proteases for early entry are the members of the
type two serine protease (TTSP) family. The TTSPs are a family of at least 17
transmembrane serine proteases that are active at the cell surface [106]. While many
TTSPs are theoretically capable of functioning as CoV activating proteases, the best
studied is the transmembrane protease serine 2 (TMPRSS2) which is important for the
entry of multiple CoVs [70, 73, 77, 82, 83, 107, 108]. TMPRSS2 performs the activating
cleavage at S2’, but only does so efficiently when encountering viruses already cleaved at
S1/S2 [65]. Viruses that are activated by TMPRSS2 bypass the late entry pathway and
likely fuse at or near the cell surface. The subcellular location of these proteases is
tightly regulated [105, 108, 109] due to potential damaging effects to organisms upon
mislocalization of transmembrane proteases [105]. Therefore, TTSPs are sequestered to
protease-rich membrane domains, likely enriched with tetraspanins, and may be scarce
elsewhere on the membrane [96].
Cathepsins are a class of proteases that are active in the late endosome/lysosomal
compartment [87] and are necessary for CoV late entry. The most important cathepsins
for CoV entry are the cysteine proteases cathepsin B and cathepsin L [62, 65, 81]. The
triggering cleavage performed by cathepsin is presumably in a region nearby the serine
protease cleavage sites [57, 61, 65]. MERS-CoV includes three putative cathepsin
cleavage sites N-terminal of the S2’ and multiple sites in the vicinity of S1/S2 [65].
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Because cathepsins are soluble, they may be able to access receptor bound S proteins
more efficiently than the serine proteases that are embedded in the membrane.
The relative expression levels of TTSPs and cathepsins in target cells have been
experimentally shown to influence the entry of CoVs. For example, MERS entry into the
TTSP-rich, but cathepsin poor Calu3 cell line is highly susceptible to serine protease
inhibitors but completely resistant to cathepsin inhibitors. Furthermore, a MERS mutant
with an S1/S2 mutation that prevents early entry was unable to efficiently enter these
cells. Similar results were seen with primary human airway epithelial cells, which
supported early entry but not late entry [65]. Many groups have observed disparate
expression of TTSPs and cathepsins in different cell lines and animal models. Cell lines
used for the isolation and testing of CoVs generally have lower TTSP expression than
primary cells and tissues, with the few exceptions being lung-cell derived cell lines like
Calu3 [65] and lung epithelial type 1 (LET1) cells [110]. This is likely due to the fact
that a high level of TTSP expression is harmful to cells in vitro [111]. Consequently,
viruses passaged in cell culture tend to favor late entry when compared to clinical
isolates. This is the case for HCoV-229E, for which clinical isolates enter cells more
rapidly and are more dependent on TTSPs than cell culture adapted viruses [79].
Furthermore, cell culture adaptation may select for CoVs with more stable S proteins as
these viruses may be more likely to survive passaging. Without the selective pressures
imposed on CoVs by in vivo infections, the stability of the S proteins may be the most
important evolutionary factor. Thus, cell culture adaptation may drive evolution of CoVs
to accumulate mutations associated with late entry.
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Tetraspanins. Recent reports have shown that these entry co-factors must be held
in close proximity by membrane scaffolding proteins called tetraspanins [96].
Tetraspanins (described below) act as scaffolds and hold CoV receptors and TTSPs in
close proximity at the cell surface. Thus, tetraspanin-rich regions on the cell surface act
as early entry portals for CoVs. Tetraspanins are known to influence the entry of MHV,
SARS, 229E, and MERS, indicating that tetraspanin utilization is a common feature of
CoV entry.
Cholesterol. Membrane cholesterol facilitates the entry of multiple CoVs [112116]. While the specific function of cholesterol in CoV entry is unknown, it is likely that
cholesterol is present in the membranes with which CoV fusion occurs. Cholesterol is
present in lipid rafts that may facilitate the interactions of tetraspanin scaffolding proteins
with their CoV-receptor partners (discussed below). Therefore, cholesterol may promote
early rather than late entry.
Tetraspanins.
Tetraspanins (see Figure 4) are a highly evolutionarily conserved family of
transmembrane scaffolding proteins that are the focus of this dissertation. There are 34
identified tetraspanins in humans, 35 in mice, and 27 in Drosophila. The tetraspanin
protein family dates back to the last common ancestor of amoebae, plants, and metazoans
[117]. The sequence conservation of tetraspanins suggests an essential role for these
proteins in regulating cell membrane processes and facilitating multicellularity. Indeed,
tetraspanins form homo- and hetero-interactions with other tetraspanin proteins as well as
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specific interactions with transmembrane partner proteins. These interactions lead to a
complex “web” of tetraspanin-mediated interactions between transmembrane proteins
(Figure 5). The study of tetraspanins encompasses diverse fields such as signal
transduction, oncology, reproduction, and of course virology.
Tetraspanin structure. Members of the tetraspanin family are highly conserved
structurally. Tetraspanins are small, 200-300 amino acid proteins that protrude 3-5 nm
from the membrane. As the name implies, each protein has four helical transmembrane
domains that are connected by a short extracellular loop (13-30 amino acids), a very
small intracellular loop, a large-extracellular loop (LEL) and short N- and C-terminal
cytoplasmic tails (Figure 4) [118]. Most of the variation observed among members of the
tetraspanin family is in the LEL. The LEL varies in length, sequence, and structure and
is the main antigenic determinant of the different tetraspanins [119].
The transmembrane (TM) domains are left-handed coiled coils that form a “cone”
in the membrane that tapers on the cytoplasmic side [118]. These domains are the most
highly conserved regions in the protein, which suggests they play an important role in
tetraspanin functions. Indeed, it is likely that the majority of tetraspanin-tetraspanin
interactions are facilitated by the TM domains. Evidence for this is given by experiments
that showed the CD151 with the LEL removed still associated with other tetraspanins
[120]. The 4 TM domains are numbered I-IV starting at the N-terminal TM domain. The
TM domains interact with each other in a specific manner, with I binding to II and IV at
different faces and so on (Figure 3, right). Conserved, polar residues in the TM regions
facilitate the homo- and hetero- interactions of tetraspanin proteins (Figure 5, left)[121].
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Furthermore, TM I is necessary for tetraspanins to leave the endoplasmic reticulum and
can perform this function without being covalently linked to the rest of the tetraspanin
molecule [122].
Zimmerman et al.’s 2016 structural study of CD81 discovered that the four TM
domains favorably form an interaction with a single cholesterol molecule (Figure 4,
right). The presence or absence of a cholesterol molecule between the four TM regions
affected not only the structure of the LEL, but also its ability to bind a partner protein.
CD81 starved of cholesterol exhibits an “open” conformation in the LEL which was

Figure 4. Structure of a tetraspanin protein. A tetraspanin protein consists of 4 helical
transmembrane (TM) domains (labeled from N-terminal to C-terminal I-IV in red) connected by
short sequences of amino acids. TM domains I and II are connected by the short extracellular
loop while TM domains III and IV are connected by the large-extracellular loop (LEL). The LEL
is largely characterized by secondary protein structures formed by intraloop interactions which
are commonly facilitated by cysteines (C). A common intraloop interaction is the C-C-G motif
depicted on this tetraspanin. A ribbon structure for the tetraspanin CD81 shows how the TM
domains surround a single cholesterol molecule (yellow). Structure work was done by
Zimmerman et al, 2016).
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shown to decrease binding to a transmembrane partner protein. Thus, tetraspanin
interactions can be regulated by altering the local concentration of cholesterol in the
membrane.
Adjacent to the TM domains are several conserved cysteine residues that are
palmitoylated under normal conditions [123, 124]. Palmitoylation of tetraspanins
facilitates hetero- interactions with other tetraspanins family members. Tetraspanins
produced in the presence of 2-bromopalmitate, which prevents palmitoylation, were
much more likely to form homodimers in the trans-Golgi network. Interestingly, there
are conflicting reports regarding whether palmitoylation affects tetraspanin interactions
with non-tetraspanin partner proteins [125, 126]. These disparate results suggest that
tetraspanin-partner protein interactions are facilitated by TM domains as well as other
domains.
The LEL is the most variable region of the tetraspanin proteins. Structural studies
of CD81 reveal the LEL to consist of multiple helices connected by unstructured regions
[118]. Three of these helices are conserved among tetraspanins while two are variable.
The conserved helices are found at the N- and C-terminal regions of the LEL and the
folded loop structure mostly contains the variable helices. All LELs contain 2-4 cysteine
pairs that participate in a disulfide bond across the loop and are necessary for proper
folding of the LEL (Figure 4, left) [127]. One of these pairs is a 100% conserved CCG
motif that is a defining feature of tetraspanin proteins.
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Figure 5. Tetraspanin interactions with transmembrane proteins. Tetraspanins are small 4-pass,
integral membrane proteins that act as scaffolds for many transmembrane proteins. A given tetraspanin can
form a homodimer with a like tetraspanin or participate in hetero- complex formations (left). Tetraspanins
likely form homo- and hetero- interactions with each other via regions in the transmembrane helices.
Tetraspanins also form specific interactions with various transmembrane proteins (middle). Tetraspanins
generally interact with transmembrane partners through their extracellular loop structures or cytoplasmic
tails. Tetraspanins that are interacting simultaneously with specific transmembrane proteins and other
tetraspanins can form important protein complexes (right). These complexes may be useful for keeping
proteins in the same signaling pathway in close proximity or for concentrating cellular factors.

Several studies have suggested that the LEL is important for tetraspanin
interactions with partner transmembrane proteins. For example, the 194QRD196 residues in
the LEL of CD151 are necessary for its interaction with integrins at the cell surface [128].
The location of this domain, on an outward face of one of the LEL variable helices,
corresponds with a putative CD9-pertner interacting motif that is responsible for spermegg fusion [129]. LELs are also important attachment points for pathogens that bind to
tetraspanins. For example, the hepatitis C virus directly binds the LEL of CD81 during
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its entry process [130]. Similarly, plasmodium parasites bind to the conserved region of
the CD81 LEL, but not CD9 [131]. These studies suggest very specific interactions
between pathogens and tetraspanin LEL regions.
Tetraspanin microdomains. A common theme of early tetraspanin research has
been that tetraspanins interact with multiple other tetraspanins and partner proteins to
form complex, semi-stable membrane microdomains at the cell surface. The evidence for
these tetraspanin-enriched microdomains (TEMs) has come primarily from coimmunoprecipitation, cross-linking, and isolation of tetraspanin-rich membrane fractions
following detergent solubilization of cells. Solubilization in certain zwitterionic
detergents like CHAPS and Brij99 can conserve membrane fractions enriched in
tetraspanins and associated proteins [132]. However, non-ionic detergents such as Triton
X-100, which are commonly used to isolate lipid rafts, ablate tetraspanin interactions.
This is one of the defining features of tetraspanin-enriched membranes and separates
them from lipid rafts [133]. Zwitterionic detergents likely maintain tetraspanin-partner
protein interaction as well as the hydrophobic interaction within the TM domains shown
to be important for tetraspanin-tetraspanin clustering [134]. However, isolation of
detergent resistant membranes does not allow for the analysis of tetraspanin dynamics in
the plasma membrane of a living cell.
Two studies, using single-molecule microscopy, have examined the nature of
tetraspanin interactions at the cell surface in intact cells. The first, performed by Espenel
and colleagues in 2008, concluded that single tetraspanin proteins cycle between
tetraspanin-rich areas and the rest of the membrane. While in the general membrane, the
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CD9 molecule exhibits Brownian diffusion, but decreased diffusion rates were observed
within the tetraspanin rich area. Building on this work, Zuidscherwoude and colleagues
used stimulated emission depletion microscopy to trace the fate of multiple tetraspanins
on the surface of living cells. They found clusters of 3-4 tetraspanins forming homointeractions (e.g. CD9-CD9 interactions) and interactions with partner transmembrane
proteins with very little direct interaction with other tetraspanin family members.
Together, these results suggest that tetraspanin interactions are less heterotypic than
previously thought. Therefore, for the purposes of this dissertation, TEMs will be
defined solely as detergent-solubilized membrane fractions and not necessarily reflect
intact, native tetraspanin complexes found at the cell surface.
Fluorescence resonance energy transfer (FRET) and proximity ligation assays
(PLA) are valuable tools for examining tetraspanin-mediated interactions beyond single
molecules in situ. FRET analysis can be valuable in identifying homo- and hetero-typic
tetraspanin interactions as well as confirming specific tetraspanin partner proteins.
However, FRET analysis has been inefficient in identifying partner protein complexes
formed by tetraspanins. Because partner proteins held together by tetraspanins do not
generally directly interact, the distance between the proteins prevents FRET. PLAs
provide a tool to investigate tetraspanin-mediated interactions that are not detected by
FRET. In PLAs, antibodies differentially tagged with oligonucleotide probes are applied
to cells, and their close spacing (<40 nm) allows for probe hybridization into DNA
polymerization templates [135], which provide a locus point for fluorescent DNA
synthesis [136]. These assays have been used to detect tetraspanin interactions with
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partner proteins [137, 138] and presumably can identify partner proteins that are held in
close proximity by tetraspanins.
General tetraspanin functions. Many roles have been described for tetraspanin
proteins in both cell culture and animal models. The majority of these roles involve
holding two or more cellular proteins in close proximity at the cell surface. Tetraspanins
do this by forming a “web” of interactions between transmembrane partner proteins and
other tetraspanins (Figure 4). Dysregulation of tetraspanin expression or localization can
lead to observable phenotypes (Table 1) and serious health problems in both humans and
mice. Through study of these phenotypes, tetraspanin proteins have been shown to be
important regulators of cell mobility, adherence, cell to cell signaling, apoptotic events,
membrane fusion events, and adaptive immune responses.
The most interesting functions of tetraspanin proteins for our studies is the role
that tetraspanins play in regulating the localization and activity of transmembrane
proteases. An example is the interaction between CD9 and the transmembrane
metalloprotease A disintegrin and metalloprotease 17 (ADAM17). It was observed that
CD9 expression negatively regulates the proteolytic activity of ADAM17, leading to
decreased shedding of tumor necrosis factor α and intercellular adhesion molecules [139].
Furthermore, the tetraspanin CD151 negatively regulates the proteolytic activity of
matrix metalloproteinase 1 leading to a decrease in degradation of the extracellular matrix
[140]. A more recent study was the first to identify an interaction between a tetraspanin,
CD81, and a proprotein convertase, subtilisin/kexin type 9, at the cell surface [137].
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These observations have important implications for enveloped virus entry that depends
on concentrated cell-surface proteases.
Tetraspanin function in viral infections. Several virus infections are facilitated
by tetraspanins. These viruses include the myxoviruses influenza A virus (IAV) [141]
and canine distemper virus (CDV) [142]; the retroviruses HIV [143, 144], feline
immunodeficiency virus (FIV) [145], and human T-lymphocytic virus 1 (HTLV-1) [146];
herpes simplex virus 1 (HSV-1) [147]; the hepatitis C virus [148]; and several human
papillomavirus (HPV) subtypes [149]. In these infections, tetraspanins facilitate viral
entry (CoVs, IAVs, HCV, HPVs) syncytia formation (CDV, HIV, FIV, HTLV-1), or
promote viral exit (IAVs, HSV-1 and HIV). Many of the functions of the tetraspanins
described in these studies is to form complexes of cellular proteins that facilitate viral
infection.
Perhaps the best studied example of a tetraspanin that facilitates viral entry is
CD81. CD81 acts as a co-receptor for the HCV E2 protein [130]. CD81 also links HCV
co-receptors scavenger receptor class B I (SR-BI) [148] and claudin-1 [150] into a
complex necessary for viral endocytosis (reviewed in [151]). Thus, CD81 acts as both a
co-receptor and a scaffolding protein holding multiple HCV entry factors together.
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Table 1. Phenotypes of CD9 deficient organisms. List of experimental knockdown (KD) and knockouts
(KO) of the tetraspanin CD9 in cell lines and mice. While CD9 deficiency is not lethal, there are a wide
variety of defects in these organisms. These studies suggest that CD9 is important in a wide array of
cellular functions including, but not limited to, motility, attachment, signaling, fusion events, and
proliferation.

Another example of a tetraspanin facilitating virus entry is the tetraspanin
CD151’s role in HPV infection. While CD151 acts as an HPV entry factor, it does not
directly interact with the virion itself (reviewed in [152]). CD151 and CD63 hold growth
factor receptors and integrins together at the cell surface. These proteins are co-receptors
for HPV and these complexes are necessary for HPV endocytosis [149].
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Two recent screens have shown that the tetraspanin CD81 is an important entry
factor for influenza A viruses [153, 154]. In both cases, CD81 was knocked down in
target cells before infection with IAV. In both cases, IAV entry into these cells was
significantly inhibited. Further studies showed that CD81 was important for both entry
and egress of IAV, but the mechanism by which CD81 facilitates these events was
unknown [141]. That tetraspanins play a role in the entry process of enveloped viruses
expressing type I viral fusion proteins led us to consider if tetraspanins may play a role in
CoV S mediated entry.
Purpose of Dissertation.
A review of the literature shows that CoVs depend on multiple host cell factors in
order to successfully enter target cells. Of these factors, receptors, transmembrane
proteases, and cathepsins have been identified and characterized. However, the
mechanisms by which receptors and transmembrane proteases interact on the cell surface
remains unknown. Productive, fusion triggering cleavage only occurs when an S protein
is bound to a receptor on the cell surface. How this occurs is not clear because the
expression and localization of transmembrane proteases is tightly regulated. Our goal
was to identify additional cellular factors that might be necessary to facilitate this
interaction and promote CoV early entry. Understanding their functions as scaffolding
proteins, we hypothesized that tetraspanins are responsible for holding CoV receptors and
priming proteases together at the cell surface and this action is required for efficient early
entry. Our results are the first to show that CoV early entry is dependent on tetraspanins
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and that CD9, specifically, interacts with DPP4 and APN and is necessary for MERS and
229E early entry routes.

CHAPTER II
EXPERIMENTAL METHODS
Cells.
Human embryonic kidney HEK cells 293T and 293β5 and MDCK cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Scientific)
supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals), 1X non-essential
amino acids, 10 mM HEPES, 1 mM sodium pyruvate, and 100 U/ml penicillinstreptomycin solution (Thermo Scientific). DBT cells were maintained in minimal
essential media (MEM) supplemented with 10% tryptose phosphate broth, 5% FBS, 100
U/ml penicillin-streptomycin, and 2 mM L-glutamine. LET-1 cells were obtained from
BEI Resources and were maintained in DMEM supplemented with 10% FBS, 100 U/ml
penicillin G, and 100 μg/ml streptomycin. Cells were maintained in a humidified
environment at 37oC and 5% CO2.
Plasmids.
Codon-optimized MERS S containing sequences for a C-terminal C9 epitope tag
was purchased from Genscript and subsequently cloned into pcDNA3.1+ between the
EcoRI and NotI restriction sites. pcDNA3.1-229E-S-C9 and pcDNA3.1-hAPN plasmids
were provided by Dr. Fang Li, University of Minnesota. pcDNA3.1-SARS-S-C9 and
pcDNA3.1-ACE2-C9 plasmids were provided by Dr. Michael Farzan, Scripps Research
Institute. pcDNA3.1-HA5-QH-trypsin site was provided by Dr. Lijun Rong, University
of Illinois-Chicago, and is previously described [155]. The pHEF-VSV-G plasmid was
35
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obtained from BEI Resources. pcDNA3.1-murine carcinoembryonic antigenrelated cell adhesion molecule (mCEACAM) was described previously [116]. C-terminal
FLAG-tagged human DPP4 plasmid pCMV6-Entry-hDPP4 (NCBI Reference Sequence
NM_001935) was purchased from OriGene. pCAGGS-TMPRSS2-FLAG and pCAGGSTMPRSS2-S441A-FLAG were previously constructed [156]. pCMVSport6-human CD9
was purchased from Open Biosystems. pSpCas9-BB-2A-puro was a gift from Feng
Zhang (Addgene plasmid # 52961). CD9 and scramble control shRNA constructs
flanked by the U6 promoter and a RNA Polymerase III stop sequence were engineered
into the pUC57 vector by Genescript. The pNL4.3-HIVluc plasmid was provided by the
NIH AIDS Research and Reference library. p

-S15-mCherry [157] was provided
EGFP

by Dr. Edward Campbell, Loyola University Chicago.
Antibodies.
Monoclonal mouse antibodies against CD9 (clone M-L13), CD63 (clone H5C6),
and CD81 (clone JS-81) were obtained from BD Pharmingen. Rabbit anti-FLAG and
anti-β-actin-HRP antibodies were obtained from Sigma Aldrich. Mouse anti-rhodopsin
(C9) antibodies were obtained from Millipore. Rabbit anti-CD13 (APN) antibodies were
obtained from Abcam. Mouse anti-CD26 (clone M-A261) was obtained from BD
Biosciences. Rabbit anti-TMPRSS2 (clone EPR3681) was obtained from Abcam.
Mouse anti-calnexin antibodies were obtained from Cell Signaling. A mouse monoclonal
antibody to IAV H1 HA (clone PY102) was provided by Dr. Balaji Manicassamy,
University of Chicago. Secondary antibodies were purchased from Invitrogen and
include goat-anti-rabbit-AlexaFluor 488, goat-anti-mouse-AlexaFluor 488, and goat-anti-
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mouse-AlexaFluor 568. Donkey-anti-goat, goat-anti-mouse, and goat anti-rabbit HRP
conjugated antibodies were purchased from Thermo Scientific.
Viruses.
Influenza A/Puerto Rico/8/1934 H1N1 (PR8) containing a Gaussia luciferase
(Gluc) reporter gene [158] was provided by Dr. Peter Palese, Mount Sinai School of
Medicine. PR8-Gluc stocks were produced using a standard protocol [159]. Briefly,
MDCK cells were inoculated with PR8-Gluc, and incubated in DMEM supplemented
with 0.2% BSA. 30 hours post infection (hpi), progeny were collected, treated with
TPCK-trypsin (Sigma), and used to infect fresh MDCK cells at MOI =1. Supernatants
were then collected, clarified by centrifugation, aliquoted and stored at -80oC. Two
strains of recombinant mouse hepatitis viruses (MHV), MHV-A59 and MHV-JHM , each
containing a firefly luciferase (Fluc) reporter gene, were produced and titered on DBT
cells as described previously [160].
Pseudoviruses.
VSV – based pseudovirus particles (pp) were produced by the methods of Whitt,
2010 [161]. Briefly, 293T cells were transfected with plasmids encoding indicated viral
glycoproteins. Two days later, cells were inoculated for 2 h with VSVΔG-luciferase
[161], rinsed extensively and incubated for one day. Supernatants were collected,
centrifuged at 800 x g for 10 min to remove cellular debris, and stored in aliquots at 80oC. HIV – based pp were produced as previously described [157]. Briefly, 293T cells
were co-transfected with pNL4.3-HIV-luc and pcDNAs encoding appropriate
glycoproteins, and where indicated, p

-S15-mCherry was also co-transfected.
EGFP
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After two days, supernatants were collected, centrifuged at 10,000 x g at 4oC for 10 min
to remove cell debris, and stored in aliquots at -80oC.
Infection in the Presence of Tetraspanin Antibodies.
DBT cells or 293β5 cells were transfected with appropriate plasmids encoding
viral receptors or proteases, divided into 96-well cluster plates, and incubated for 30 min
at 37oC with indicated antibodies, at 0.12 µg/µl (~107 antibodies / cell). Indicated viruses
were then added for 2 h at 37oC, then cells were rinsed, incubated at 37oC for 6 h (MHV
and PR8), 16 h (VSV), or 48 h (HIV). For PR8, cells were not lysed, and media were
analyzed for secreted Gluc. For the other viruses, cells were lysed in passive lysis buffer
(Promega). Luciferase levels in media or lysates were measured after addition of either
Fluc substrate (Promega) or Gluc substrate (New England Biolabs) using a Veritas
microplate luminometer (Turner BioSystems).
Flow Cytometry.
To measure antibody binding, 293β5 cells were lifted with Accutase (Millipore),
pelleted and resuspended to 106 cells/ml in phosphate buffered saline (PBS)
supplemented with 2% FBS containing indicated antibodies at 0.12 µg/µl. After 30 min
at 37oC, cells were rinsed thrice by pelleting and resuspension in PBS-2% FBS, then
incubated for 30 min at 4oC with AlexaFluor 488 – conjugated donkey-anti-mouse IgG.
After sequential rinsing, cell fluorescence was detected using a BD C6 Accuri flow
cytometer. To measure HIV pp binding, 293β5 cells, transfected with empty pCMV6 or
with pCMV6-Entry-hDPP4, were suspended in PBS-2% FBS. Cells were divided and
aliquots were incubated for 30 min at 37oC with tetraspanin antibodies at 0.12 µg/µl.
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Cells were chilled, then incubated for 1h on ice with HIV-mCherry-MERS S. Cells were
rinsed thrice by pelleting and resuspension, and mCherry fluorescence detected using a
BD C6 flow cytometer. All flow cytometric data were analyzed using FlowJo software.
Fluorescence Activated Cell Sorting.
DBT cells were transfected with 0.5 μg of pEGFP, and a total of 4 µg of a
pCAGGS empty vector or TMPRSS2 plasmid per 106 cells. 24 h after transfection, cells
were lifted with trypsin, washed 3 times with cold PBS supplemented with 2% FBS, and
sorted using a BD Biosciences FACSAria cell sorter. Live, GFP+ cells were plated and
incubated at 37oC overnight before antibody blockade experiments were performed as
described above.
Immunofluorescence Microscopy.
293β5 cells were transfected with indicated plasmid DNAs, incubated for two
days, and then cooled to room temperature (RT). Antibodies and HIV-mCherry pps were
added, cells incubated for 30 min at RT, 10 min at 37oC, then returned to RT.
AlexaFluor – conjugated secondary antibodies were applied for 10 min at RT, along with
Hoechst 33258 (Molecular Probes). Cells were rinsed with PBS, fixed with 3.7%
paraformaldehyde in 100 mM PIPES buffer [pH 6.8], mounted using PermaMount, and
imaged with a DeltaVision microscope (Applied Precision) equipped with a digital
camera (CoolSNAP HQ; Photometrics), using a 1.4-numerical aperture 60X objective
lens. Images were deconvolved with SoftWoRx deconvolution software (Applied
Precision). Co-localization was measured and quantified using Imaris version 6.3.1
(Bitplane Scientific Solutions).
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Isolation of Tetraspanin-enriched Membranes.
Adherent 293β5 cells (~105 / cm2) were rinsed with ice-cold PBS, incubated for
30 min at 4oC with 1 mg / ml EZ-Link Sulfo-NHS-LC-Biotin (Pierce) in PBS, rinsed,
then incubated for 20 min at 4oC with 100 mM glycine in PBS. Cells were rinsed with
PBS, then incubated for 20 min at 4oC in MES buffer (25 mM MES [pH 6.0], 125 mM
NaCl, 1 mM CaCl2, 1 mM MgCl2) containing 1% 3-[(3Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) detergent
(Calbiochem Cat # 220201) or 1% TritonX-100 detergent (Sigma). Cell lysates (107 / ml)
were removed from plates and emulsified by 20 cycles of extrusion through 27G needles.
Nuclei were removed by centrifugation, lysates mixed with equal volumes of 80% w/v
sucrose in MES buffer, placed into Beckman SW60 tubes, and overlaid with 3 ml of 30%
w/v sucrose, then with 0.5 ml of 5% w/v sucrose, both in MES buffer. Samples were
centrifuged with a Beckman SW60 rotor at 370 K x g for 18 h at 4oC. Fractions were
collected from air-gradient interfaces. Biotinylated proteins in gradient fractions were
bound to streptavidin agarose beads (Pierce). Non-reducing dot- and western-blotting
procedures were used to identify the distributions of proteins in gradient fractions, as
described previously [162].
Virus Priming Assays.
PR8 or MERS pp were incubated at 37oC for 30 min with equal volumes of lowdensity (LD) or high-density (HD) sucrose gradient fractions, or with 2.5 U trypsin /
reaction (in 50 μl total) (Sigma). Treated PR8 and MERS pp were divided, and proteins
in one set of aliquots were precipitated with trichloroacetic acid and analyzed by western
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blotting. The other set were used to transduce 293β5 cells. Cells transduced with MERS
pp were pre-treated for 1h with or without 10 μM leupeptin (Sigma), inoculated for 2 h,
rinsed and incubated without leupeptin for 18 h. Cells were then lysed and luciferase
levels were measured. Cells infected with PR8 viruses were infected at an MOI=1, rinsed
after 2 h, and incubated for an additional 6 h. Media were collected and Gluc levels were
measured.
Production of Knockout Cell Lines.
pSpCas9-BB-2A-puro was digested with Esp3I (Fermentas) for 4h at 37oC. The
digested plasmid was purified and ligated with annealed guide DNAs specific for CD9 or
CD81. Tetraspanin-specific pSpCas9-BB-2A-puro plasmids were transfected into 293T
cells. After 72h, cells were selected with 4 µg/ml puromycin for 96h. Selected cells
were serially-diluted to isolate clonal populations and clones were selected by western
blot.
Proximity Ligation Assay.
HeLa cells were transfected with indicated plasmid DNAs and a GFP reporter,
incubated for two days, and then lifted from tissue culture plates using 0.05% trypsin.
Cells were transferred to microscope coverslips coated with fibronectin. Cells were
allowed to adhere for 24h. Cells were then fixed for 30 minute at 37oC with 3.7%
paraformaldehyde in 0.1 M piperazine-N,N′-bis(2-ethanesulfonic acid) buffer (pH 6.8).
Coverslips were washed with PBS and PLA was performed using DuoLink® Proximity
Ligation Assay (Sigma-Aldrich) using primary antibodies against TMPRSS2 and CD26.
Images were captured using a DeltaVision microscope (Applied Precision) equipped with
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a digital camera (CoolSNAP HQ; Photometrics), using a 1.4-numerical aperture 60X
objective lens. Images were deconvolved with SoftWoRx deconvolution software
(Applied Precision). PLA foci were detected and quantified using Imaris version 6.3.1
(Bitplane Scientific Solutions).
Protease Inhibitor Assays.
293T cells were transfected with DPP4 and an empty vector or the
complementing tetraspanin. Cells were pre-treated for 1h with 100 µM camostat, 100
µM bafilomycin, or 10 µM E64D before transduction with MERS pps in the presence of
the inhibitors. After 2h, cells were washed to remove drugs and unadsorbed virus.
Luciferase assays were performed as described above.
Entry Kinetics Assay.
293T cells were transfected with DPP4 and either an empty vector or
complementing tetraspanin. 24h after transfection, cells were plated in a 96-well plate.
MERS pps were added to cells at 4oC for 1 hour to allow viral binding. Media was
removed and replaced with 37oC media and the plates were moved to an incubator. At
sequential time points following the shift to 37oC, a protease inhibitor cocktail was added
to cells such that the final concentration was 100 µM bafilomycin, 10 µM E64D, and 100
µM camostat. These drugs were left on cells overnight before cells were lysed and
luciferase was measured as described above. Luciferase levels were compared to that of
cells treated only with DMSO control.
Cholesterol Depletion Assay.
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293T cells were transfected with DPP4 and either an empty vector or
complementing tetraspanin. After 2 days, cells were plated in serum-free media for 18 h
before treatment with the indicated concentration of methyl-beta-cyclodextrin (Sigma)
for 4 h. Cells were transduced with HIV-MERS pp for 2 h. Cells were washed to
remove virus and cyclodextrin and allowed to incubate for 48h. Cells were lysed and
lysates were analyzed for luciferase reporter gene expression as described above.
HR2 Inhibition Assay.
DBT cells were pretreated with the indicated concentration of MERS HR2
peptides (kindly provided by Dr. Matteo Porotto) tagged through maleimide reactions
with lipid moieties. After 30 min, cells were infected with rMHV-A59, rMHV-JHM, or
100 pfu MHV-2. 1 hpi, cells were washed to remove virus and peptides. For rMHV-A59
and rMHV-JHM, the cells were incubated for 18 h and lysed. MHV infection was
measured by luciferase assay as described above. For MHV-2, cells were covered with
0.5 % agarose in complete media. 48 hpi, cells were fixed with 10 % paraformaldehyde
for 10 minutes and stained with a 1% crystal violet solution at RT for 2 h. Agar was
removed and cells were washed with water 3 times. Plaques were then counted.

CHAPTER III
RESULTS
SECTION 1: Tetraspanin-rich Membranes as Viral Entry Portals.
Tetraspanin antibodies inhibit infection of coronaviruses and influenza A.
We hypothesized that tetraspanins function as scaffolding proteins holding viral entry
factors together. To determine whether entering CoVs utilize tetraspanins, we evaluated
the effects of tetraspanin antibodies on MHV strains A59 and JHM infections. Murine
DBT cells were incubated for 30 min with mouse monoclonal antibodies against the
tetraspanins CD9, CD63, CD81, or with an equimolar mixture of the three (αTspan). A
monoclonal antibody against transferrin receptor (TfR) was used as an isotype – matched
control for general cell coating by antibodies. Cells were then inoculated with luciferaseexpressing recombinant MHV-A59 or –JHM for 2 h, then unadsorbed viruses and
antibodies were rinsed away. As measured by luciferase levels at 8 hpi, the two viruses
were significantly inhibited by all three tetraspanin antibodies, with the antibody
combination (αTspan) inhibiting A59 and JHM strains by ~50% and ~90% , respectively
(Figure 6A). The TfR antibodies did not block the viruses. None of the antibodies
interfered with transduction by VSV pps bearing VSV G proteins (VSV pp), indicating
that tetraspanin antibodies do not generally suppress virus entry or reporter gene
expression.
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Figure 6. Effect of tetraspanin antibodies on MHV and IAV infection. (A) DBT
cells were treated with monoclonal antibodies to CD9, CD63, CD81, or an equimolar mixture of
the three (αTspan) for 30 min. Cells were then infected with rMHV-A59 or rMHV-JHM viruses
containing an Fluc reporter gene. 8 hpi, infection was quantified by measuring Fluc reporter gene
products and were normalized to the untreated controls. A control VSV-G pseudotyped reporter
virus was also used (VSV pp). A monoclonal antibody against transferrin receptor (TfR) was
used as a control for both antibody subtype and irrelevant cell binding. Results are representative
of three independent experiments. *p<0.05 when compared to “No Ab”. (B) Cells transfected
with an empty vector (EV) or the indicated amounts of HAT were infected with a PR8 influenza
virus containing a Gluc reporter gene. 8 hpi, media was sampled from cells and analyzed for
secreted Gluc. (C) 293β5 cells transfected with 0.001 µg/106 cells of HAT were treated with
antibodies as described in (A). This experiment also included a non-specific Mouse IgG control
antibody (M Ig). Media was sampled and analyzed for secreted Gluc 8 hpi. *p<0.05 when
compared to “No Ab”.
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While it is known that CD81 knockdown inhibits IAV entry [141], it is not known
whether antibodies to CD81 or other tetraspanins also inhibit IAV infection. We
determined whether the tetraspanin antibodies inhibit influenza A/Puerto Rico/8/1934
(H1N1), also known as PR8 IAV. For ease of analysis, we used PR8 containing a
Gaussia luciferase (Gluc) reporter gene [158]. Many host cells, including the cell lines
used in these experiments (Figure 6B), are resistant to PR8 infection, because they do not
express proteases that prime viral HA proteins. [163]. Therefore, we transfected 293β5
cells with plasmids encoding HAT, then infected with PR8 one day later. By measuring
Gluc accumulations in culture media, we determined that transfecting cells with 0.001
µg/106 cells of HAT was sufficient to render cells susceptible to PR8 infection and that
increasing HAT transfection generally led to increased infection (Figure 6B). Knowing
this, we determined whether tetraspanin antibodies might block PR8 infection into the
HAT-expressing cells. Indeed, PR8 infection was significantly inhibited by all three
tetraspanin antibodies, with the antibody combination (𝛼𝛼Tspan) effecting ~ 50%
blockade. The tetraspanin antibodies did not inhibit VSV pp transductions (Figure 6C).
Tetraspanin antibodies inhibit entry of several coronaviruses. To limit our
analyses to virus-cell entry, we produced VSV-based pps that contained the S proteins of
several human CoVs, and determined whether their ability to transduce cells was blocked
by tetraspanin antibodies. The virus preparations were designated according to their S
proteins (MERS pp, SARS pp, 229E pp). Their transduction into cells was taken to
reflect features of the authentic MERS, SARS and 229E CoV entry processes [156, 162].
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Transduction-susceptible target cells were established by transfecting 293β5 cells with
genes encoding virus receptors; hAPN for HCoV-229E [103], hDPP4 for MERS-CoV
[100], and hACE2 for SARS-CoV [102]. These target cells were then inoculated with the
pp preparations, in the absence or presence of tetraspanin antibodies, as was done with
authentic viruses. After 1 h inoculation periods, unadsorbed pps and antibodies were
removed, and transduction levels measured the next day by quantifying Fluc gene
expressions.
The tetraspanin antibodies impaired transductions by all three CoV pps, with
MERS pp and SARS pp most notably inhibited (Figure 7). The only exception was 229E
pp which was not blocked significantly by the antibody against CD81. As seen
previously, TfR antibodies did not affect transductions nor did the IgG isotype control.
Tetraspanins inhibit entry following receptor binding. To determine whether
the antibodies used for virus blockades bound similarly to target cells, we subjected
antibody-coated cells to flow cytometry. The inert TfR antibodies and inhibitory
tetraspanin antibodies bound similarly (Figure 8A), indicating that virus blockades do not
arise simply from high levels of antibodies on cells. Next, to determine whether
antibodies on cells interfere with virus-cell binding, we used fluorescently-labeled, HIVbased MERS pps, which we manufactured according to previously described methods
[157]. mCherry MERS pps were adsorbed at 4oC to 293β5 cells overexpressing hDPP4
receptors, either in the absence or presence of tetraspanin antibodies. Subsequent flow
cytometric analyses revealed that the fluorescent HIV-based MERS pps bound
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Figure 7. Effect of tetraspanin antibodies on CoV pseudotyped virus cell entry. 293β5 cells overexpressing appropriate receptors (APN for
229E, DPP4 for MERS, ACE2 for SARS) were treated with monoclonal antibodies to CD9, CD63, CD81, or an equimolar mixture of the three
(αTspan). After 30 min, cells were transduced with pps pseudotyped with S proteins of 229E (black), MERS (gray), or SARS (hatched).
Transduction levels were measured by quantifying Fluc reporter gene products and were normalized to the “No Ab” controls. Mouse IgG (M Ig)
and a monoclonal antibody against transferrin receptor (TfR) were used as controls for antibody subtype and irrelevant cell binding, respectively.
Results are representative of three independent experiments. *p<0.05 when compared to the “No Ab” controls.
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abundantly to the ~35% of cells that were overexpressing hDPP4 (Figure 8B, left). The
level of MERS pp binding to the ~ 35% of cells was unaffected by tetraspanin antibodies
(Figure 8B, right). We concluded from these data that the antibodies do not block viruscell binding.
These data also indicated that tetraspanin antibodies interfere with virus entry
after virus-receptor binding. To explain how the antibodies block viruses, we posited that
viruses might associate with TEMs after binding to cells, and that the tetraspanin
antibodies disrupt some tetraspanin-associated process that facilitates virus entry. We
determined whether the mCherry MERS pps reside in close proximity to tetraspanin
proteins during their cell entry. To do this, we incubated chilled 293β5 cells with the
fluorescent pps along with anti-CD81 antibodies, then shifted to 37oC for 10 min to
permit “patching”, i.e., antibody-mediated tetraspanin cross-linking into larger structures
[164]. Quantitative confocal microscopy revealed that CD81 colocalized with ~20% of
MERS pps, but with only ~10% of VSV pps (Figure 8C, right). Absence of “bald”, i.e.
viral glycoprotein free, fluorescent pp binding (Figure 8C, left) confirmed viral
glycoprotein-dependent interactions with cells. Similar, but less compelling co-patching
of IAV pp and CD81 were also observed in these experiments, however IAV pp colocalization was not statistically significantly higher than VSV pp (Figure 8C). These
data indicate that, shortly after binding to cells, some MERS and IAV pp are present near
tetraspanin proteins.

50

Figure 8. Immunofluorescent analysis of pseudoparticle binding to cells in the presence of
tetraspanin antibodies. (A) Flow cytometric analysis of the binding efficiencies of the
antibodies used in tetraspanin blockade experiments in figures 6 and 7. 293β5 cells were
incubated without antibodies (black) or with the indicated antibodies. Following a 30 min
incubation, cells were washed and incubated with an anti-mouse AlexaFluor-488 (AF488)
secondary antibody. AF488 intensity was measured by flow cytometry. (B) 293β5 cells
overexpressing DPP4 (+DPP4) or an empty vector (-DPP4) were incubated with MERS-S
pseudotyped HIV-mCherry for 1 h at 4oC. Following incubation, cells were washed of unbound
virus and analyzed by flow cytometry to detect mCherry. The percentage of mCherry-positive
cells is indicated above the gate (left panel). +DPP4 cells were treated with αTspan antibodies.
After 30 min at 37oC, HIV-mCherry-MERS pseudoviruses were inoculated for 2 h at 4oC.
Following washing of unadsorbed virus and antibody, flow cytometry was performed to detect
bound HIV pseudoviruses (right panel). (C) HIV-mCherry pseudoviruses without glycoproteins
(Bald) or with VSV G, IAV HA, or MERS S, were mixed with anti-CD81 antibodies and
inoculated onto +DPP4 cells for 30 min at 4oC. After a 10 min, 37oC patching period, cells were
fixed and analyzed by confocal microscopy to determine the location of the pseudoviruses (red)
and CD81 (green). Co-localization of CD81 and HIV-positive puncta were quantified using
Imaris software. Data were plotted as percent of HIV pseudoviruses that were localized to CD81.
The experiments in (C) were performed by Dr. Jung-Eun Park.
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Using MERS pp, we further determined that tetraspanin antibodies were
inhibitory only at the pp entry stage, with no effects on transduction when added 30 min
following virus inoculation (Figure 9). These data, considered with the data in Figure 8,
led us to the conclusion that tetraspanin antibodies inhibit an early stage of entry,
following virus binding.
Tetraspanin antibodies do not block infection when TTSPs are
overexpressed. One of the major roles of tetraspanins is regulating transmembrane
protease location on the cell surface. To do this, tetraspanins are known to partner with a
variety of cell-surface proteases [165], among which may be one or several CoV and IAV
-priming proteases [73, 156, 163, 166]. This led us to hypothesize that tetraspanin
antibodies interfere with tetraspanin-facilitated proteolytic priming, possibly by
preventing tetraspanin-associated proteases from accessing receptor-bound viruses. By
this hypothesis, CoVs which can access non-tetraspanin-associated TTSPs should not
rely on tetraspanins for entry, and thus should be unaffected by tetraspanin antibodies.
To address this suggestion, we overexpressed priming proteases in target cells and
performed antibody blockade experiments. One frequently-cited CoV priming protease
is TMPRSS2 [73, 83]. We found that DBT cells expressing human TMPRSS2 were
hypersensitized to MHV infection, indicating that this protease is utilized by MHV and is
limiting in the DBT cell context. Therefore, we supplied DBT cells with graded doses of
TMPRSS2 – encoding plasmids, along with small constant amounts of a GFP reporter
plasmid. Following expression, FACS was used to isolate the GFP+ cells, which were
then used in antibody blockade experiments, as described above (Figures 6 and 7). The
results indicated that tetraspanin antibodies blocked MHV infection into normal DBT

52

Figure 9. Tetraspanin antibodies block CoV entry at an early stage. 293β5 cells were
incubated without antibodies (No Ab), with control anti-transferrin receptor antibodies (αTfR), or
with a mixture of anti-tetraspanin antibodies (αTspan) for 30 min periods immediately before (30) or after (+30) a 60 min MERS pp pseudovirus inoculation period. Transduction levels were
measured by quantifying luciferase and were normalized to the “No Ab” control. *p<0.05 when
compared to “No Ab”.
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Figure 10. Effect of transmembrane protease expression on tetraspanin blockade of MHVJHM and PR8. (A) DBT cells were transfected with increasing amounts of TMPRSS2 plasmid
and a small amount of GFP reporter. Following isolation of transfected cells by FACS, cells were
treated with either a mixture of tetraspanin antibodies (+Tspan) or media (-Tspan). After 30 min,
cells were infected with rMHV-JHM. 2 hpi, cells were washed to removed unadsorbed virus and
antibody. 8 hpi cells were lysed and analyzed for Fluc reporter expression. Luciferase units were
normalized to the average number of cells infected under each condition. (B) 293β5 cells were
transfected with increasing amounts of HAT before being exposed to the same antibody blockade
experiment described in (A). Cells were infected with PR8 for 2 h, washed, and secreted Gluc
was measured 8 hpi.
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cells (Figures 6A and 10A), but not into DBT cells expressing TMPRSS2 (Figure 10A).
Of note, 106 cells transfected with 0.004 µg of TMPRSS2 plasmid contained TMPRSS2
protein levels that were far below our western blot and immunofluorescent assay (IFA)
detection limits, making it clear that even small amounts of priming proteases will bypass
the tetraspanin antibodies (Figure 10A). We speculate that overexpressing TMPRSS2 in
cell lines overwhelms the ability of tetraspanins to regulate the localization the protease.
Data using biochemical isolation and proximity ligation assay (PLA) (Figures 17, 21, and
22) which show large amounts of non-tetraspanin associated TMPRSS2 suggest this may
be the case. However, definitive data on this subject remains elusive. Regardless, we
conclude from these data that overexpressed TTSPs overcome the dependence of viruses
on tetraspanins.In similar experiments, PR8 and its priming protease HAT were evaluated
in entry assays. Here, 293β5 cells were transfected with graded doses of HAT-encoding
plasmids, and then infected with PR8, either in the absence or presence of tetraspanin
antibodies. The results indicated that HAT bypassed the antibody blockades in a dosedependent manner (Figure 10B). Furthermore, trypsin pre-treated viruses also bypassed
the antibody blockades (Figure 10B). Therefore, the hypothesis that proteases mitigate
the antiviral activities of tetraspanin antibodies applies to TMPRSS2, HAT and trypsin
proteases, and to MHV and PR8 viruses.
Protease treated viruses are not blocked by tetraspanin antibodies. Trypsin is
often used as a surrogate for TTSPs and other serine proteases in labs that study
enveloped virus entry. Trypsin treatment cleaves the S1/S2 region of MERS pps and
destabilizes them to a degree, possibly relieving MERS dependence on tetraspanininduced concentration of TTSPs for entry. Alternately, trypsin-cleaved MERS may
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utilize endosomal proteases much more efficiently than uncleaved MERS for S
triggering. Therefore, we hypothesized that upon trypsin treatment, MERS pp is less
likely to rely on TTSPs and tetraspanins for entry. To investigate this, we pre-treated
MERS pps with 2.5 units of trypsin for 10 minutes. After inactivating the trypsin, we
performed the antibody blockade experiments described previously. As expected,
uncleaved MERS pp entry into target cells was less efficient in the presence of antitetraspanin antibodies. However, when pretreated with trypsin, MERS pp entry into
target cells was almost entirely independent of tetraspanin antibody blockade (Figure 11).
These results corroborate the similar bypass of antibody blockade observed upon
overexpression of TTSPs.
Biochemical analysis of tetraspanin-enriched membranes. Our findings fit
with the hypothesis that tetraspanins facilitate the interaction of viral receptor and
priming proteases. Antibody binding to tetraspanins interferes with these encounters,
reducing infection. To further evaluate the interactions of CoV entry factors and
tetraspanins, we used a biochemical approach to determine whether cell receptors and
priming proteases are present within TEMs. Surface-biotinylated 293β5 cells were lysed
in buffers containing CHAPS, a zwitterionic detergent that emulsifies cell membranes
without disrupting primary or secondary TEM interactions [132]. After sucrose density
gradient fractionation, CHAPS-soluble proteins remained near the bottom of sucrose
gradients, designated as the high-density (HD) regions, while CHAPS-insoluble proteinlipid complexes floated to the top, low-density (LD) (ρ<1.13 g/ml) regions. Dot-blotting
revealed that ~ 20% of biotinylated (plasma membrane) proteins were in the LD region
(Figure 12, upper left). Streptavidin pulldowns of the isolated HD and LD fractions
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revealed that within the top 20% were all detectable cell-surface CD9, CD63, and CD81
proteins (Figure 12, lower left), indicating that the LD region includes the TEMs.
Notably, cells lysed by Triton X-100 (TX-100), a detergent known to solubilize TEMs,
also generated an LD fraction that comprised ~20% of plasma membrane proteins (Figure
12, upper right), but was devoid of any cell-surface tetraspanins (Figure 12, lower right).
Thus, we confirmed that CHAPS LD subcellular fractions represent “TEMs” and the TX100 LD fractions as “lipid rafts”.

Figure 11. Effect of tetraspanin antibodies on entry of trypsin pre-treated MERS pp.
MERS pseudoviruses were either untreated or preprimed with 2.5 units of trypsin for 30 min
before being used in a TEM blockade experiment as described previously (Figure 5). Before
addition to cells, any trypsin was neutralized using soybean trypsin inhibitor. Transduction
efficiency was determined by reporter gene expression. Results are representative of three
independent experiments. *p<0.05 when compared to “Untreated” control.
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Figure 12. Biochemical isolation of tetraspanin enriched membranes. 293β5 cells were
surface-biotinylated before lysis with CHAPS or TX-100 detergent. Following differential
centrifugation, 10 fractions were collected from each tube and analyzed by dot blot using a
streptavidin HRP for total-cell surface, biotinylated proteins (top). Following collection of HD
and LD fraction, streptavidin pulldowns were performed and each fraction was analyzed for cell
surface CD9, CD63, and CD81 (bottom).

To determine whether CoV receptors and priming proteases partition into TEMs,
it was necessary that 293β5 cells were first transfected to overexpress ACE2, APN,
CEACAM, or DPP4. The transfected cells were then lysed in CHAPS, and TEMs
isolated by two sequential cycles of floatation on sucrose gradients. Western
immunoblotting revealed that ~ 90% of ACE2, APN, and CEACAM and ~ 50% of the
DPP4, were partitioned into TEM fractions (Figure 13).
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Cells overexpressing the virus-priming proteases TMPRSS2 and HAT were
similarly fractionated, and roughly 50% of these proteases were found in the TEM
fractions (Figure 13). TMPRSS2 can self-proteolyze, releasing the extracellular domain
into the media. Thus, the ability to detect intact, closely complexed TMPRSS2 in cell
membranes may be limited. To avoid this issue, we expressed a proteolytically inactive
TMPRSS2 mutant (TMPRSS2S441A) and found that it more prominently partitioned into
the TEM fractions (Figure 13). We concluded from these data that TTSPs concentrate in
TEMs. Some β-actin (<10%) partitioned with TEMs, consistent with known TEM –
cytoskeleton interactions [167]. Calnexin, a transmembrane protein abundant in the
endoplasmic reticulum [168], was excluded from the TEMs, indicating complete cell
solubilization by CHAPS detergent. Attempts to isolate non-TEM associated proteins
failed, but there is evidence that inclusion in CHAPS-LD fractions is dependent on
protein interaction with tetraspanins (Figure 21).
As the TEM fractions contain ~ 20% of the total plasma membrane proteins, these
results indicated that the CoV receptors and priming proteases were at least 5- to 50-fold
more abundant in TEMs than elsewhere on cell surfaces. TEM localization of one CoV
receptor (DPP4) and one priming protease (TMPRSS2) was validated by
immunofluorescence microscopy. DPP4 and TMPRSS2 were both found near or within
CD81-encriched cell-surface puncta (Figure 14). Similar partitioning of CD81 with a
catalytically-inactive mutant TMPRSS2S441A was also observed (Figure 14), indicating
that enzymatic activity has no effect on subcellular localization. Thus, there are
recognizable proportions of CoV receptors and priming proteases residing within TEMs.
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Figure 13. Analysis of CoV entry factors in tetraspanin enriched membranes. 293β5 cells
overexpressing epitope-tagged CoV receptors ACE2, APN, CEACAM, and DPP4, or FLAGtagged TTSPs TMPRSS2, TMPRSS2-S441A or HAT. Transfected cells were subjected to
CHAPS lysis and density gradient centrifugation, as described in figure 10. Western blot was
used to determine the relative presence of the indicated proteins into HD and LD fractions. βactin and calnexin were used as controls for complete cell lysis and proteins not present in
CHAPS LDs.
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Tetraspanin-enriched membranes productively cleave viral glycoproteins.
Because TEMs contain both viral receptors and priming proteases, we determined
whether the isolated TEMs have virus-priming activities. Like exogenously cleaved
MHV in Figure 11, we expected that pre-cleaved MERS-CoV would become less reliant
on cellular TTSPs for entry. We mixed TEMs with MERS pps, inoculated the mixtures
onto susceptible target cells and then measured transduction efficiencies. To ensure that
the transduction measurements reflected proteolytic priming by the TEMs, and not by
endogenous target cell proteases, we suppressed target 293β5-cell priming proteases with
leupeptin, a broad-spectrum protease inhibitor. Leupeptin-treated 293β5 cells were
profoundly resistant to MERS pp transduction (Figure 15A; top), indicative of
requirements for the host proteases. However, MERS pp that were exposed to TEM
fractions transduced the leupeptin-treated cells (Figure 15A, top), indicating priming. Of
note, the bypass of leupeptin was pronounced when MERS pp were exposed to trypsin, or
to TEMs containing overexpressed TMPRSS2, but did not reach the levels observed in
the absence of leupeptin. These findings indicated that MERS entry-priming activities
were greatly concentrated in the TEMs.
MERS pp that had been exposed to TEMs were also evaluated to assess the
extents of S protein cleavage. Western immunoblots indicated that the TEMs effected
cleavage of S proteins, generating proteolytic patterns that were largely indistinguishable
from those generated by trypsin (Figure 15A; bottom). The apparent molecular weights
of the N-linked glycoprotein products were consistent with cleavages at three multibasic
sites, one at amino acids 626-629 (RQQR) to create the minor 130 kDa fragment, one at
884-887 (RSAR) S2’ site to create the major 70 kDa fragment, and one at 1110-1113
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Figure 14. Localization of MERS-CoV entry factors DPP4 and TMPRSS2 in relation to
tetraspanin CD81. 293β5 cells were transfected with plasmids encoding the indicated FLAGtagged proteins. 24 h later, live cells were co-incubated with anti-FLAG and anti-CD81
antibodies, with a 10 min incubation at 37oC to induce patching. Fluorescent secondary
antibodies were applied to mark the positions of FLAG-tagged proteins and CD81, and Hoescht
33258 (blue) mark the positions of cell nuclei. Images show 0.5-micron thick confocal slices
through the top section of cells. These experiments were performed by Dr. Jung-Eun Park.
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(QSKR) to create the minor 40 kDa fragment. Somewhat surprisingly, cleavage of
MERS at S2’ prior to encountering the cell did not completely inactivate the virus. This
may be due to incomplete cleavage of all the S proteins or because S1 failed to dissociate
from S2 under these conditions. Interestingly, TEM-mediated cleavage of S proteins led
to less generation of the 40 kDa fragment when compared to trypsin treated S. We
speculate that the cleavage that generates this fragments may be inactivating and may be
less prevalent when TEM-associated receptors are bound to S proteins simultaneous to
cleavage, as seen previously [65].
Analogous experiments were completed with IAV PR8 viruses. In these assays,
however, inactivation of host proteases by leupeptin was not required, as PR8 did not
respond to endogenous levels of 293β5-cell proteases. The results of these experiments
demonstrated that TEM fractions activated PR8 infectivities, nearly as much as TEMs
with overexpressed HAT (Figure 15B, top). The fact that the TEMs were isolated from
IAV-resistant 293β5 cells, yet were capable of priming IAV for infection, are potentially
explained by the significant concentration of cell proteases achieved through TEM
isolation.
As with the MERS S on viral pps, PR8-associated HA proteins were analyzed for
cleavage status by western immunoblotting. Here, the TEMs effected cleavage of HA0
into HA1, irrespective of whether HAT was overexpressed and equal to that achieved by
trypsin (Figure 15B; bottom). Thus, the TEM fractions harvested from 293β5 cells have
proteases that cleave and prime both MERS-CoV S and PR8 IAV HA proteins.
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Figure 15. Virus priming activity of TEMs. (A) MERS pps were used to transduce 293β5
cells treated with leupeptin or a media control. Prior to transduction, MERS pps were treated
with trypsin, TEMs isolated from untransfected cells, or TEMs isolated from TMPRSS2
overexpressing cells. Transduction levels were measured by luciferase reporter gene expression
(top). The MERS pps were also concentrated and analyzed by western blot with an antibody to
detect a C-terminal C9 tag on the MERS spike (bottom) (B) 293β5 cells were infected with PR8
that was treated with trypsin, TEMs isolated from untransfected cells, or TEMs from HAT
overexpressing cells. Infection was measured by Gluc expression (top). Viruses were
concentrated and analyzed by western blot (bottom). *p<0.05 when compared to “–“ incubation

SECTION 2: CD9 as an Entry Factor for HCoV-MERS and HCoV-229E.
Our initial discoveries provided insight on how tetraspanin interaction with viral
entry factors may affect CoV and IAV entry into target cells. However, the role of
individual tetraspanins remained to be investigated. We hypothesized that CoV receptors
and priming proteases had individual tetraspanin binding partners that facilitated their
interaction with other tetraspanin-associated proteins. We therefore endeavored to
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identify the individual tetraspanins that facilitate TTSP-mediated CoV entry and
characterize tetraspanin-dependent CoV entry.
There is evidence that CD9 directly interacts with the MERS receptor DPP4. The
first indication comes from studies of biochemically isolated of TEMs, similar to
described above, in which CD9 was immunoprecipitated (IP). Mass spectrometry
identified DPP4, along with many other transmembrane proteins, as a protein that co-IPs
with CD9 under these conditions [165]. More recently, a direct interaction between CD9
and DPP4 was identified by co-IP of the proteins under detergent conditions that
solubilize TEMs [169]. Therefore, we hypothesized that CD9 may be the specific
tetraspanin partner that is responsible for holding DPP4 in close proximity with TTSPs
and thus for MERS early entry (Figure 3). Furthermore, we aimed to determine if CD9
was a common entry factor for all CoVs or if it plays a specific role in MERS entry.
In order to investigate these questions, we produced CD9 knockout (KO) cell
lines. These cells permitted complementation assays to be performed to determine the
role of the tetraspanins CD9 and CD81. We then analyzed the efficiency and nature of
CoV entry in the presence and absence of these tetraspanins as well as the localization of
CoV entry factors. To analyze these tetraspanins in the context of authentic viral
infections of host lungs, we developed novel methods of knocking down or knocking out
CD9 in host organisms. A member of our lab, Mike Hantak, along with our colleagues at
the University of Iowa, developed an adenovirus 5 (Ad5) transgene expression system
that allowed for targeted knockdown of CD9 in virus target cells. With these tools, we
identified CD9 as an entry factor for MERS-CoV and 229E-CoV that facilitates rapid,
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TTSP-dependent early entry of these viruses. Furthermore, we quantified the entry
efficiency of MERS-CoV in lung cells deficient in early entry factors.
Tetraspanin knockout cell lines. Analyzing the potential role of tetraspanins in
CoV entry events necessitated the creation of tetraspanin KO cell lines. With these cells,
we could analyze viral entry in the presence and absence of a specific tetraspanin. We
chose CD9 and CD81 as our tetraspanin target because both were indicated to participate
in CoV entry in our antibody experiments (Figures 6 and 7) and both typically reside on
the cell surface, unlike CD63.
We used CRISPR/Cas technology [170] to remove selected tetraspanins from
cells. 293T and HeLa cells were transfected with Cas9/guide RNAs targeting CD9 or
CD81, selected for puromycin resistance, and cloned by endpoint dilution. All KO cell
lines grew equivalent to parallel “WT” control clones, and the only observable
distinctions were with the CD9KO cells, which were slightly less adherent than WT or
CD81KO cells. For the clones used in this study, western blot analyses were performed
and the results confirmed the absence of CD9 or CD81, with maintenance of a control
tetraspanin CD63 (Figure 16A). Interestingly, CD9 appeared slightly reduced in
CD81KO cells. However, IFA of unpermeabilized cells showed similar cell-surface
expression and localization of CD9 in WT and CD81KO cells (Figure 16B). IFA also
confirmed the absence of the respective tetraspanins in KO cells. CD63 distribution
remained unchanged in all cell lines.
CD9 inhibits MERS and 229E entry, but not MHV or SARS. We measured
the entry of CoVs into tetraspanin-deficient cells to determine which, if any, CoVs
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Figure 16. Analysis of tetraspanin KO cells. (A) Western blot analysis of 293T and HeLa
clonal cell lines knocked out for the indicated tetraspanin. Actin and the tetraspanin CD63 are
used as loading controls. (B) Immunofluorescent analysis of HeLa clonal cell lines.
Unpermeabilized cells were incubated with primary antibodies against CD9, CD81 or CD63 as
indicated.
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depend on either tetraspanin for entry. To focus on S-mediated entry, we utilized pp
transduction. We first sensitized the cells to transduction by overexpressing CoV
receptors, then transduced cells with the respective CoV pps. Relative to WT cells,
CD9KO cells were 94% less susceptible to MERS pp transduction (Figure 17A), a result
that reflects the data. Furthermore, we found CD9KO cells were 80% less susceptible to
229E pp transduction (Figure 17B), indicating that CD9 acts as an entry factor for 229ECoV as well as MERS-CoV. However, CD9KO cells remained fully susceptible to
SARS pp or MHV pp transduction (Figure 17C and D). As expected, CD9
complementation restored susceptibility to MERS pp and 229E pp transductions (Figure
17A and B).
CD81 KO cells were fully susceptible to all four of the CoV pps (Figure 18). The
lone exception is a statistically insignificant decreased in SARS pp entry into CD81KO
cells. These data along with those in Figure 17 suggest that CD9, but not CD81, acts as a
specific tetraspanin partner for MERS-CoV and 229E-CoV entry factors. Furthermore,
CD9 does not affect an entry factor common to all CoVs.
Our previous results using tetraspanin antibodies suggested that CoV reliance on
tetraspanins correlated with TTSP expression levels in target cells. We found that
massive overexpression of these proteases bypasses CoV reliance on tetraspanins (Figure
10) which we believe is likely due to high levels of non-tetraspanin associated TTSP
localization (Figures 13 and 21). Therefore, we hypothesized that MERS and 229E entry
into the CD9KO cells was less efficient because the viruses were significantly less likely
to encounter priming TTSPs at the cell surface. To test this hypothesis, we overexpressed
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TMPRSS2 in the CD9KO cells. Like our observations with antibody experiments
(Figure 10), overexpression of TMPRSS2 in the CD9KO cells eliminated the effect of
CD9 depletion on both MERS and 229E entry (Figure 19). Furthermore, TMPRSS2
overexpression alone significantly increased entry of all CoV pps (compare Figures 17
and 19).

Figure 17. COV-S mediated entry into CD9 knocked out 293 cells. 293T WT or CD9KO
cells were transfected with appropriate receptors and either an EV or CD9 where indicated.
These cells were transduced with HIV pseudoviruses carrying S proteins of MERS (A), 229E (B),
SARS (C), or MHV (D). Pseudovirus transduction was measured using luciferase assay.
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CD9 is required to deposit DPP4 and APN into tetraspanin-enriched
membranes. The observation that a single tetraspanin family member, CD9, facilitated
cell entry for some, but not all CoVs, suggested the existence of specific interactions
between CD9 and one or more MERS-CoV and 229E-CoV entry factors. We considered
whether CD9 directs DPP4 and APN, the MERS-CoV and 229E-CoV receptors, to
TTSP-enriched membrane microdomains. Furthermore, we considered whether CD9
does not direct ACE2 and CEACAM, the receptors for CD9-independent SARS-CoV and
MHV. This was first investigated through biochemical isolation and analysis of TEMs
for CoV entry factors, as described above (Figures 12 and 13). To this end, CD9 or
CD81 KO cells overexpressing CoV receptors or TMPRSS2 were surface-biotinylated,
solubilized in CHAPS detergent, and membrane fractions were separated by 2 rounds of
differential centrifugation. After streptavidin pulldown, HD and LD fractions were
analyzed for CoV entry factors.
Strikingly, the LD fractions from WT control cells contained ~60% of cell-surface
DPP4, while LD fractions from CD9KO cells completely lacked DPP4 (Figure 20A, rows
1 and 2). Complementing CD9 back into CD9KO cells restored LD-associated DPP4
(Figure 20A, row 3). The presence or absence of CD81 had no effect on DPP4
distribution between HD and LD fractions (Figure 20A, rows 4 and 5). Similar results
were observed with the

70

Figure 18. CoV Transduction of CD81KO 293T cells. 293T WT or CD81KO cells were
transfected with appropriate receptors and either an EV or CD81 as indicated. These cells were
transduced with HIV pseudoviruses carrying the indicated CoV S proteins as in figure 16.
Pseudovirus transduction was measured using luciferase assay.
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Figure 19. Effect of TMPRSS2 overexpression on transduction of CD9KO cells. 293T WT or
CD9KO cells were transfected with TMPRSS2 and the appropriate viral receptor as in figure 16.
Cells were transduced with the indicated pseudovirus. Transduction levels were measured by
luciferase assay.
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229E receptor APN (Figure 20B). By contrast, CD9 and CD81 expression had little effect
on the distribution of ACE2, CEACAM, or TMPRSS2, all of which distributed about
equally between LD and HD fractions (Figure 20C-E). These data indicate that the
positioning of DPP4 and APN into TEMs requires CD9, which suggests that CD9
interacts with these receptors and co-localizes them with other tetraspanin-associated
proteins, such as TMPRSS2. The fact that CD9 repositioned DPP4 and APN, but not
ACE2 or CEACAM, correlated with the fact that CD9 facilitated DPP4- and APNutilizing MERS and 229E pps, but not ACE2- or CEACAM-utilizing SARS and MHV
pps.
CD9 holds DPP4 and TMPRSS2 in close proximity. As discussed in Chapter I
and observed in Figure 12, TEMs can accurately identify tetraspanin partner proteins.
However, these collected membrane fractions likely do not accurately reflect interactions
in the tetraspanin web in intact cells. Therefore, we endeavored to analyze tetraspaninmediated interaction of CoV entry factors in situ. Specifically, we attempted to
determine if CD9 facilitates the close interaction of the MERS entry factors DPP4 and
TMPRSS2 in target cells. To this end, we performed proximity ligation assays (PLAs),
which can determine whether two or more transmembrane proteins are adjacent [135], in
CD9KO cells. As discussed in Chapter I, PLA allows for detection of proteins that are
within 40 nm.
HeLa cells were chosen for PLA assays because their relatively flat morphology
facilitated quantification of fluorescent foci. CD9KO HeLa cells transfected with
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Figure 20. Association of CoV entry factors with CHAPS-resistant membranes in the presence or absence of CD9 or CD81. 293T WT,
CD9KO, or CD81KO cells were transfected with the CoV receptors DPP4 (A), APN (B), ACE2 (C), CEACAM (D), or the protease TMPRSS2
(E). KO cells were also complemented with the appropriate tetraspanin as indicated on the left. Cell-surface proteins were biotinylated before
cells were lysed in cold CHAPS and cleared lysates were subjected to differential centrifugation. Cell surface proteins were isolated by
streptavidin pulldown and analyzed in high density (HD) and low density (LD) fractions by western blot.
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combinations of CD9, DPP4, and/or TMPRSS2 proteases, were fixed on fibronectincoated coverslips and incubated with primary antibodies against these proteins.
Following secondary antibody incubation and amplification of ligated oligonucleotide
templates, punctate fluorescent DNAs were detected by confocal microscopy and counted
using Imaris version 6.3.1 software.
Using hDPP4 and hTMPRSS2 antibodies, fluorescent foci were rarely observed
on the HeLa-CD9KO cells (Figure 21A). Foci were ~ 10-fold more abundant after
transfection with CD9 alone (Figure 21D), indicating that CD9 alone was responsible for
connecting these two entry factors. These results were corroborated under conditions in
which hDPP4 and hTMPRSS2 were exogenously overexpressed. With overexpression of
both proteins, ~30 foci/cell were observed (Figure 21E), and this increased to ~80
foci/cell in the presence of CD9 (Figure 21F). Transduction experiments indicated that
MERS pp entry into cells correlated with the number of foci present, at least at values up
to ~30 foci/cell (Figure 21H). We speculate that the ~30 foci/cell observed in
DPP4/TMPRSS2 overexpressing CD9- cells is sufficient to maximize susceptibility to
MERS pp which explains the similar transduction levels observed in the CD9- and CD+
cells (compare Figure 21G and 21H). Thus, these results indicated that CD9 connects the
DPP4 and TMPRSS2 entry factors together, and suggest that cell surface complexes of
DPP4, TMPRSS2, and CD9 function as MERS-CoV entry portals.
These data suggest that exogenous overexpression of proteins overwhelms the
ability of endogenous tetraspanins to localize/sequester them in tetraspanin-rich regions.
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Figure 21. Proximity ligation assay of DPP4 and TMPRSS2 in CD9KO cells. (A-F) HeLa CD9KO cells were transfected with the indicated
genes and a GFP reporter before being mounted on microscopy slides. Proximity ligation assay was performed using primary antibodies against
hDPP4 and hTMPRSS2. Red dots indicate close proximity of the two proteins. (G) The average number of foci/cell in GFP+ cells in each group
was quantified. (H) MERS pp transduction of HeLa cells overexpressing the indicated proteins.
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This can potentially explain why TMPRSS2 alleviated inhibition of MERS entry by
tetraspanin antibody blockade and CD9KO (Figures 10 and 19), as overexpressed
TMPRSS2 was no longer fully sequestered in tetraspanin-rich regions. Regardless, in
overexpressing cells, TMPRSS2 and DPP4 proximity was either more common or more
stable in cells expressing CD9 (Figure 21H).
MERS entry kinetics in CD9-deficient cells. CoVs can enter cells through early
or late entry routes depending on protease availability (see Figure 3). While early entry
requires fusion-activating TTSPs at the cell surface, late entry requires fusion-activating
endosomal cathepsins [65, 66]. Because CD9 brought DPP4 in proximity with one of
the TTSPs, we hypothesized that CD9 facilitates rapid, early cell entry. To test this, we
performed entry kinetics assays. In these assays, MERS pps are bound to cells at 4oC to
synchronize viral-cell binding, then shifted to 37oC to allow entry for timed intervals.
MERS entry was halted by adding a nontoxic protease inhibitor cocktail and quantified
relative to entry into untreated control cells (experiment was adapted from[79]). Since
CoVs cannot complete fusion in the presence of these inhibitors, the transduction
readouts indicate the extent of virus entry taking place within the inhibitor-free time
periods.
MERS pp entry rates were slowed in the absence of CD9 (Figure 22A).
Compared to WT cells, the initiation of entry into CD9KO cells was delayed by 10
minutes and remained significantly delayed until 1 hour after temperature shift, when all
measured viral fusion had occurred (Figure 22A). Complementation of CD9 into the
CD9KO cells
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Figure 22. Entry kinetics of MERS pp in tetraspanin KO cells. The entry kinetics of MERS
pps were measured in 293T WT, CD9KO (A), and CD81KO (B) cells. Cells were bound with
MERS pps and incubated with entry inhibiting protease cocktail at the indicated time point.
Luciferase levels were measured and plotted relative to untreated control cells. (C) Entry kinetics
into KO cells complemented with cells overexpressing TMPRSS2. *p<0.01 compared to WT
cells.
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restored MERS pp entry kinetics to those observed with WT cells (Figure 22A). MERS
pp entry into CD81KO cells was nearly identical to the WT cells (Figure 22B). Thus, we
concluded that CD9 facilitates rapid MERS entry into target cells. From these data, we
also speculated that late entering viruses begin to fuse between 15-20 min after cell
binding and that late entry can take up to 60 min.
We have observed that TMPRSS2 overexpression can alleviate CoV dependence
on tetraspanins for entry. Specifically, forced overexpression of TMPRSS2 made MHV
resistant to tetraspanin antibody blockade (Figure 10), obviating the need for CD9 in
MERS pp entry (Figure 19), and led to a large number of DPP4/TMPRSS2 foci in PLA
(Figure 21). Therefore, we posited that MERS entry into TMPRSS2-overexpressing cells
would be both rapid and CD9 independent. As expected, WT and KO cells that
overexpressed TMPRSS2 were similarly susceptible to a very rapid MERS virus entry,
with 50% of maximal entry by 10 min, regardless of CD9 or CD81 expression (Figure
22C).
MERS protease utilization in CD9-deficient cells. As discussed in Chapter I
(see Figure 3), CoV early entry depends on TTSPs, which are inactivated by the serine
protease inhibitor camostat [73]. Since our data suggest that MERS early entry is CD9dependent, we expected that MERS pp entry in CD9KO cells would not rely on these
camostat-sensitive proteases. To test this, we transduced DPP4 overexpressing 293T
WT, CD9KO, and CD81KO cells. Camostat suppressed MERS pp transduction into WT
cells by ~50% compared to untreated cells, but did not affect transduction into CD9KO
cells (Figure 23A). CD9 complementation modestly restored
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Figure 23. Protease utilization of MERS pp entry in tetraspanin KO cells. (A) WT or KO
cells were transfected with DPP4 and either an empty vector or the complementing tetraspanin as
indicated. The cells were pretreated with camostat before transduction with MERS pps. MERS
entry was measured by luciferase assay and the percent transduction levels of viruses into
camostat treated cells is plotted relative to untreated cells (dotted line). (B) WT or KO cell lines
were transfected with DPP4 and either an empty or the complimenting tetraspanin as indicated.
The cells were pretreated with bafilomycin or E64D before transduction with MERS pp. MERS
entry was measured by luciferase assay.
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MERS pp sensitivity to camostat to around 70% of transduction of untreated cells.
Furthermore, CD81 had no effect, as MERS pp entry into CD81KO and CD81-positive
cells were equally suppressed by camostat and indistinguishable from WT cells (Figure
23A). These data suggest that camostat-sensitive early entry requires CD9.
Previous studies in our lab have characterized a MERS S mutation that prevent
participation in early entry. This mutation changes the amino acids in the S1/S2 cleavage
site from the furin target RSVR (see Figure 2) to a serine-protease resistant YSAS.
MERS pps produced with the S1/S2 mutant enter cells in a manner independent of TTSP
activity and completely dependent on cathepsins. We hypothesized that CD9 depletion
would have no effect on a virus that cannot participate in early entry. As expected,
YSAS pp transduction of target cells was inefficient compared to WT and was
completely independent of CD9 expression (Figure 24). From this, we concluded that
CD9 plays no role in MERS late entry.
Without CD9, the MERS pp entry may be forced to late, endosomal routes in which
cathepsins provide fusion-activating triggers (see Figure 3). To test this, we blocked late
entry in WT and CD9KO cells by introducing two inhibitors of endosomal cathepsins.
Cells were pretreated with 100 μM bafilomycin A (Baf) or 10 µΜ of the cysteine
protease inhibitor E64D before transduction with MERS pp. In WT cells, Baf did not
significantly decrease entry, while E64D decreased entry ~4-fold (Figure 23B).
However, in CD9KO cells, these inhibitors were far more antiviral, decreasing entry 20and 100-fold, respectively. Complementing CD9 back into the CD9KO cells restored the
WT condition in which the inhibitors were only weakly antiviral (Figure 23B). CD81
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expression had no effect on cathepsin-dependence (Figure 23B). From these results, and
from the entry kinetics assays (Figure 22), we inferred that CD9 is necessary for early,
cell-surface cell entry by MERS-CoV.

Figure 24. Effect of CD9 expression on MERS S1/S2 mutant. 293T WT and CD9KO cells
were transfected with DPP4 and either an EV or CD9. Cells were transduced with MERS pp
produced with an S containing a WT RSVR (black) or YSAS (gray) S1/S2 cleavage site. The
YSAS mutant has been shown to enter cells through late entry. Transduction of cells was
measured using luciferase assay.
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Cholesterol depletion inhibits infection in CD9-deficient cells. Recent
structural studies of the tetraspanin CD81 revealed that the transmembrane domains
associate with a single molecule of cholesterol [118]. Furthermore, the presence or
absence of cholesterol was shown to affect the ability of CD81 to associate with partner
proteins. As discussed in Chapter I, cholesterol has commonly been identified as an entry
co-factor for a variety of CoVs, including MERS [171] and MHV [116] but the
mechanism for this is unclear. We hypothesized that cholesterol mediates the interaction
of tetraspanins and CoV entry factors. Thus, cholesterol depletion of target cells would
interfere with tetraspanin-mediated early entry of MERS-CoV. If this were the case,
MERS entry into CD9KO cells would be cholesterol independent. To test this
hypothesis, we serum starved 293T CD9KO cells, transfected with DPP4 or CEACAM,
before treating the cells with methyl-beta-cyclodextrin (MβCD), a cholesterol chelating
agent. We transduced these cells with CD9-independent MHV pp or MERS pp.
Cholesterol starvation rendered WT and CD9KO about 30% and 40% resistant to MERS
and MHV transduction, respectively at 10 mM cyclodextrin (Figure 25). There was no
significant difference observed between the susceptibility of WT and CD9KO cells to
either pp. Higher doses of cyclodextrin were likely lethal to target cells. While these
results did not support our hypothesis, further studies using tetraspanin mutants incapable
of binding cholesterol may obviate the need for drug treatment and allow us to draw
conclusions on cholesterol’s effects on early entry.
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Figure 25. Effect of cholesterol depletion on CoV entry into CD9KO cells. 293T WT or
293T CD9KO were transfected with DPP4 (for MERS pp) or CEACAM (for MHV pp). Cells
were serum-starved and treated with the indicated concentration of MβCD for 4 h before
transduction with MERS pp or MHV-A59 pp. Cells were washed after 2 h and pseudovirus entry
was measured by luciferase assay.

SECTION 3: Importance of Early MERS-CoV Entry in Mice.
No study to date has determined the relative importance of CD9 or TMPRSS2mediated early entry in MERS-CoV infection in the lung environment. Indeed, there are
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34 human tetraspanins and at least 17 members of the TTSP protease family [106] as well
as several soluble extracellular proteases, such as elastases [73], in the lung parenchyma,
making it unclear whether CD9 or TMPRSS2 stand out in vivo as the single necessary
proviral members of their respective protein families. Therefore, we attempted to
determine whether and to what extent MERS-CoV utilizes CD9 and TMPRSS2 during in
vivo infection. To this end, we established a mouse model in which virus-resistant mice
are rendered susceptible to MERS-CoV infection by expression of human DPP4
(hDPP4). The system utilizes an adenovirus type 5 (Ad5) to transduce the hDPP4 gene,
thereby sensitizing only the Ad5-transduced lung cells to subsequent MERS-CoV
infection [172]. The Ad5-hDPP4 vectors were engineered to include additional genes
encoding human TMPRSS2 or potential virus-restricting factors, in the form of shRNAs
targeting murine Tmprss2 and Cd9. We considered the Ad5-hDPP4 system to be
especially valuable, as MERS-CoV infection can only occur in cells expressing hDPP4
and, thus, only in cells simultaneously expressing the putative virus-promoting or virusrestricting factors. Therefore, the dual-expressing Ad5 vectors might be excellent tools to
rapidly obtain clean results that identify in vivo pro- and anti-viral host factors.
Adenovirus vectored knockdown of CD9 and TMPRSS2 in target cells. Our
mechanistic insights of CD9-mediated MERS early entry encouraged us to determine the
importance of CD9 and early entry in vivo. However, we first determined whether the
rAd5 constructs could manipulate protein expression in mouse cells in vitro. We tested
the following rAd5 vectors: rAd5-hDPP4-hTMPRSS2, the shRNA-encoding rAd5hDPP4-shTmprss2 and rAd5-hDPP4-shCd9, and the control viruses rAd5-hDPP4-empty
and rAd5-GFP. We chose to test these constructs in the Lung Epithelial Type 1 (LET1)
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cell line which was derived through immortalization of alveolar type 1 cells from
C57/Bl6 mice [110]. LET1 cells were transduced with the rAd5 vectors at MOI 10.
Following a 3 d incubation, the cells were lysed and analyzed for the presence of DPP4,
TMPRSS2, and CD9 by western blot (Figure 26A). Cells transduced with the control
rAd5-GFP had detectable levels of CD9, but barely detectable levels of DPP4 and
TMPRSS2. The respective experimental Ad5 vectors produced abundant, recognizable
DPP4 and TMPRSS2, and those Ad5 vectors expressing shRNAs reduced the levels of
endogenous CD9 proteins (Figure 26A). These results indicate that the rAd5 vectors,
transduced into cells derived from mouse alveolar epithelia, consistently and equally
express hDPP4 while simultaneously increasing or decreasing TMPRSS2 or CD9.
Experiments examining rAd5-hDPP4-shTmprss2 knockdown of an endogenously
expressed, detectable level of TMPRSS2 are ongoing.
Knockdown of CD9 and TMPRSS2 inhibit MERS-CoV infection. We
determined whether the rAd5-transduced LET1 cells were susceptible to MERS-CoV S
protein-directed virus entry. To this end, the cells were inoculated with the rAd5s for 3 d
before being transduced with MERS pp. As expected, cells transduced with Ad5-GFP
were resistant to MERS pp entry due to lack of hDPP4 receptors. Cells transduced with
any of the Ad5-hDPP4 vectors were permissive (Figure 26B). TMPRSS2 expression
from the Ad5 vectors increased permissivity to MERS pps by ~ 4-fold, while shTmprss2
and shCd9 both restricted MERS pps by ~3 fold (Figure 26B). These results indicated
that CD9 and TMPRSS2 act as entry factors in mouse lung-derived LET1 cells, and
suggested that the dual-expressing Ad5 vectors might be effective tools for identifying
viral entry factors in the mouse lung.
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Figure 26. Analysis of Adenovirus mediated knockdown of CD9. (A) LET-1 cells were
transduced with an adenovirus carrying a GFP gene or an adenovirus carrying hDPP4 and either
an empty vector, the TMPRSS2 gene, or a U6-driven shRNA against TMPRSS2 or CD9. After 3
days, cells were lysed and analyzed by western blot for the indicated proteins. (B) LET1 cells
were transduced with the indicated Ad5 vector before transducing with MERS pp. Transduction
was measured by luciferase assay. (C) The indicated Ad5 vector were installed intranasaly in
C57/Bl6 mice. 3 days later, mice were infected with MERS-CoV. 2 dpi lungs were isolated and
viral titers were measured by plaque assay. The experiments in (C) were performed by Dr. Kun
Li at the University of Iowa.
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To identify the role of CD9 and TMPRSS2 in vivo, the Ad5 vectors were
intranasally installed into mice, allowed to express transgenes for 5 d, and then
challenged with MERS-CoV (strain HCoV-EMC/2012). Lungs were harvested 2 days
post-infection (d.p.i.) and MERS-CoV titers were measured as plaque forming units
(PFU)/gram of tissue. Relative to MERS-CoV titers in rAd5-hDPP4 transduced animals,
the MERS-CoV titers in rAd5-hDPP4-shCd9 transduced animals were ~20-fold lower
(Figure 26C). Furthermore, the MERS-CoV titers in rAd5-hDPP4-shTmprss2 transduced
mice were reduced by ~10-fold.

Interestingly, overexpression of TMPRSS2 by the

rAd5-hDPP4-TMPRSS2 vector had no effect on MERS-CoV titers in the lungs,
presumably because the lung environment has sufficient endogenous TMPRSS2 to
facilitate efficient MERS-CoV infection. These data indicate that CD9 and TMPRSS2
act as MERS-CoV susceptibility factors in the lung parenchyma and that their role in
entry is more pronounced in vivo than in in vitro LET1 mouse alveolar cell cultures.
Indeed, these data show that CD9 and TMPRSS2 are responsible for ~90% of MERSCoV titers in vivo.
SECTION 4: Membrane-targeted Antiviral Small Molecules.
One of the advantages of identifying the subcellular location of CoV fusion
reactions is being able to target these areas with antiviral drugs. HR2 peptides, as
discussed in Chapter I, can be effective in blocking enveloped virus entry. However, to
do so, the peptides must encounter viral glycoproteins in the meta-stable extended
intermediate state (see Figure 1). This conformation is likely short-lived in CoVs which
limits the effectiveness of HR2 peptides as antiviral therapies for CoVs.
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Previous studies have shown that tagging HR2 peptides with lipid moieties can
increase their effectiveness in blocking enveloped virus fusion [173]. We hypothesized
that CoV HR2 peptides targeted to the specific subcellular location of viral entry would
show similar efficacy. Surprisingly, Dr. Jung-Eun Park found HR2 peptides derived
from MERS can potently inhibit MHV infection, despite little amino acid conservation in
the HR1 regions of the two viruses. We took advantage of this by analyzing lipid-tagged
HR2 blockade of early and late entering MHV strains. MHV-A59 and MHV-JHM utilize
early entry as evidenced by their reliance on tetraspanins (Figure 6) and utilization of
TMPRSS2 (Figure 10A). Conversely, MHV strain 2 (MHV-2) uses the late entry route
almost exclusively, due to the lack of an ideal serine protease cleavage site at S1/S2 [63].
Therefore, we hypothesized the HR2 peptides tagged with cholesterol and palmitic acid,
which likely accumulate at the cell surface and possibly near tetraspanin-rich regions
[131, 174], would effectively block MHV-A59 and -JHM but not MHV-2. However,
HR2 peptides tagged with tocopherol, which would likely accumulate in the endosome
[175], would preferentially block a late entering virus like MHV-2.
Lipid-conjugated HR2 peptides potently inhibit MHV infection. To test the
efficacy of lipid-tagged HR2 peptides, we infected DBT cells with rMHV-A59 and -JHM
in the presence of the peptides. We obtained, from our collaborator Dr. Matteo Porotto,
HR2 peptides tagged with maleimide chemistry to cholesterol, palmitic acid, or
tocopherol through a polyethylene glycol (PEG) linker. As controls, we used untagged
HR2 peptides and HR2 peptides only tagged with the PEG linker. When pretreated with
the cholesterol- and tocopherol- tagged HR2 peptides, DBT cells became significantly
more resistant to infection by MHV-A59 and -JHM (Figure 27). In both cases, the
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palmitic acid nearly eliminated infection when used as a 1 µM dose. Untagged and PEG
tagged had little effect on MHV-A59 infection and no effect on MHV-JHM infection.
Interestingly, the tocopherol-tagged HR2 peptides showed only limited efficacy against
these two viruses and only at the highest dose. These results were consistent with our
hypothesis that cholesterol and palmitic acid-tagged, but not tocopherol-tagged, HR2
peptides can be targeted to early entry events.
Tocopherol-tagged HR2 peptides only inhibit late-entering MHV-2 strain.
To further investigate the role of the lipid tags in increasing HR2 peptide efficacy, we
determined if a late entering MHV-2 virus would be more effectively inhibited by a
tocopherol-tagged HR2 than the early entering MHVs. We performed a MHV-2 plaque
reduction assay using the untagged, cholesterol tagged, and tocopherol tagged HR2
peptides. Interestingly, we found that tocopherol tagged HR2 peptides had a lower ED50
than the cholesterol tagged HR2 (Figure 28, solid lines). These data support our
hypothesis that lipid tags target the HR2 to specific subcellular locations. To further
investigate this, we manipulated the MHV-2 entry route by pre-treating the virus with
trypsin. While trypsin destabilized the MHV-2 viruses and decreased their specific
infectivity, it also likely allowed the virus to participate in early entry and expose
extended intermediate conformations at the cell surface. Following trypsin treatment, the
efficacy of the cholesterol-tagged HR2 peptide increased dramatically (Figure 28, dashed
lines). However, the efficacy of the tocopherol tagged HR2 decreased by a similar
degree. These data strongly suggest that the lipid tags increase HR2 efficacy by targeting
the peptides to the specific membranes at which CoVs participate in fusion.
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Figure 27. Inhibition of MHV infection by lipid-tagged HR2 molecules. DBT cells were
incubated for 30 min with the indicated concentrations of HR2 peptides with no modification (No
Tag), a polyethylene glycol linker (PEG), or the PEG linker attached to tocopherol (Toco),
palmitic acid (Palm), or cholesterol (Chol). Cells were infected with rMHV strain A59 or JHM as
indicated. 8 hpi, cells were lysed and infection was measured by luciferase assay. *p<0.01,
**p<0.001 compared to untreated cells.
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Figure 28. Inhibition of MHV-2 infection by lipid-tagged HR2 peptides. DBT cells were
incubated for 30 min with the indicated HR2 molecule. Concurrently, 100 pfu of MHV-2,
pretreated for 10 minutes with media (-trypsin) or 2.5 units trypsin (+trypsin), was mixed with
soybean trypsin inhibitor and inoculated onto the cells. 1 hpi, cells were washed of unbound
virus and HR2 and immobilized in agar. 2 dpi, cells were fixed, stained and plaques were
counted. Plaque reduction is plotted as % plaques compared to the “No HR2” control.

CHAPTER IV
DISCUSSION

Summary and Significance.
We endeavored to identify and characterize CoV entry routes and the cellular
factors that contribute to early entry. We found that expression of receptors and
transmembrane proteases is not sufficient for CoV early entry. Our results are the first to
demonstrate this phenomenon and are also the first to identify tetraspanins as CoV entry
factors. Furthermore, our results expand on what was previously known about
tetraspanin-facilitated enveloped virus entry, especially the role of tetraspanins in IAV
infections. Our studies found that all tested CoVs, as well several influenza A subtypes,
depend on tetraspanins for efficient entry into target cells. Furthermore, we identified
CD9 as a MERS and 229E-CoV entry factor and defined its role in holding viral
receptors and the protease TMPRSS2 in close proximity at the cell surface. Our results
indicate that enveloped viruses that require multiple entry factors likely evolve to utilize
complexes that form from natural cellular processes and are not induced by viral binding
or infection. Our membrane scaffolding model may be generalizable to other enveloped
viruses which participate in cell-surface fusion events.
While previous studies have suggested that early entry is important in vivo, our
studies are the first to quantify the effect removing early entry factors from mouse lungs
92
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has on MERS-CoV infections. Our collaborators and we did this with recombinant
adenoviruses (rAd5), which sensitize experimental animals to CoV infection [172]. By
incorporating RNA silencing genes into rAd5 viruses carrying hDPP4, we were able to
analyze the role of CD9 and TMPRSS2 as relevant proviral factors. This approach
involving dual-expressing adenovirus vectors can potentially be utilized to identify any
MERS-CoV or other zoonotic virus host factor. The system does not require timeconsuming and costly establishment of transgenic mice, like those used in studies of
SARS [176] and MERS [177], to perform in vivo analyses of novel human CoV entry
factors. Importantly, the Ad5 dual-expression system has additional advantages over
transgenic animals, since the modulation of pro- and anti-viral factors is always restricted
to the virus-susceptible cells, making for robust readouts of any change in virus
susceptibility. Using this system, we determined that >90% of MERS-CoV titers in
mouse lungs depends on CD9 and TMPRSS2.
In addition to characterizing in vivo MERS infections, we used our observations
of tetraspanin-mediated early entry to design antiviral therapies. We observed that lipidtagging HR2 peptides could increase their antiviral efficacy by almost 1000-fold. Using
our knowledge of the subcellular location of different entry routes, we were able to
predict which lipid tags would be most effective at blocking early vs. late entering strains
of MHVs. Further analysis of CoV entry factors will allow for the development of an
expanded repertoire of rAd5 and HR2 antiviral therapies.

Early and Late CoV Entry.
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Most enveloped viruses exhibit little variation in the subcellular location of
membrane fusion, but CoVs exhibit a great flexibility in this regard. As discussed in
Chapter I, there are two broad categories of subcellular location at which enveloped
viruses fuse and deliver their genetic materials; i) direct fusion at cell surface (e.g., HIV,
paramyxovirus) and ii) fusion out of the endosome (e.g., influenza, flavivirus)[178].
Cell-surface early entry occurs in less time than late entry (Figure 25). A variety of host
factors are necessary to facilitate CoV early entry in target cells. These factors are
present to facilitate the interaction of viral receptors and priming proteases at or near the
surface of the cell. We determined that these factors are held together by tetraspanins at
the cell surface (Figure 22). In the absence of early entry factors, CoV entry is dependent
on cathepsins (Figure 23).
While we have defined the cellular factors required for each entry route, we are
just beginning to measure which entry pathway is more relevant in vivo. Data from our
collaborators strongly suggest that MERS infection of mouse lungs is acutely sensitive to
knockdown of cellular early entry factors (Figure 26). These data agree with
observations that late-entering MERS-CoVs inefficiently infect lung-derived Calu3 and
human epithelial cell cultures [65] and clinical isolates of HCoV-229E preferentially
utilize cell surface proteases [79]. Furthermore, the role of early entry in vivo has also
been inferred in a study that determined that serine protease inhibitors render mice
resistant to SARS-CoV infection to a significantly greater degree than cathepsin
inhibitors [74]. These results taken together suggest that CoVs evolve S proteins that can
utilize cell surface TTSPs for early entry.
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These hypotheses may have significant relevance in regards to isolation and
characterization of future pandemic CoVs. SARS and MERS were both identified
following growth of the virus in cell culture, a common tactic for identifying novel
pathogens. While the prototype SARS virus was identified following only one passage in
Vero cells [179], the prototype MERS strain HCoV-EMC/2012 was passaged 6 times in
Vero cells before characterization [180] and likely acquired several cell culture
adaptation mutations. Importantly, the experiments described above suggest that cell
culture adaptation can occur quickly and that the mutations that arise in cell culture can
severely attenuate viruses in vivo. Thus, we suggest that accurate analysis of pandemic
CoV entry factors require direct sequencing of patient samples.
Our conclusion that early entry is more efficient in vivo does not explain why
CoVs retain the ability to participate in late entry. One possibility is that the integrity of
tetraspanin clusters is interrupted by increases in temperature, as seen in lipid rafts [181],
upon onset of fevers. This may lead to late entry being preferred during late stages of
CoV infection. Another possibility is that the unstable structures of CoV S needed for
early entry decrease the ability of CoVs to spread between hosts. This has been observed
with pandemic influenza A viruses, which acquire more pH stable HA glycoproteins over
time. This increase in stability correlates with increased transmission among in humans
and ferrets, especially via the airborne route [182]. It is possible that the ability to
undergo late entry is a byproduct of CoV S stability. Furthermore, the ability to utilize
both entry routes may allow CoVs to infect various cell types that have disparate
expression of CoV entry factors, such as tetraspanins, TTSPs, and cathepsins. This
ability may increase CoV host range. Thus, we propose that late the mechanisms that
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lead to late entry in CoVs may provide an evolutionary advantage to these viruses,
especially in their ability to spread between hosts.

Benefits of Early Entry.
Early entry allows for rapid infection of target cells. Furthermore, S proteins that
are suited for early entry are also more likely to lead to cell-cell fusion of infected cells
and may facilitate easier cell-cell spread of infectious virions. The early entry route also
bypasses certain, potent innate immune effectors such as interferon induced
transmembrane proteins [77, 171, 183] and the humoral immune response [70].
Perhaps the most important benefit of early entry is that it bypasses the
requirement of late entry in the endosomal compartments. This late entry route requires
furin proprotein convertases [59, 92] and / or cathepsin L [57, 61, 77], cathepsin B [63],
cathepsin K [73] cleavage of S proteins in the late endosome. However, the late
endosomal environment can be very rich in proteases and other hydrolases [87], which
probably generate inactivating cleavages of CoV proteins. There are several observations
of S protein fragments, 40 kDa and smaller (Figure 15, for example), that are consistent
with permanent inactivation [65, 184]. Therefore, there may be a short time span between
a cathepsin-activated fusogenic state and a permanently inactivated, excessively
proteolyzed state during virus entry. This may account for inefficient late entry.
Inefficient late entry may also be explained by differences in lysosomal and plasma
membranes, which have unique lipid profiles [185] and therefore may be differentially
susceptible to S -catalyzed fusion.
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Model of Tetraspanin-mediated CoV Early Entry.
Our results indicate that tetraspanins are necessary for efficient entry of CoVs into
target cells. Furthermore, we characterized tetraspanin-mediated entry events as TTSPdependent early entry. We propose a model for CoV early entry that is dependent on
tetraspanin scaffolding of multiple viral early entry factors into close proximity (Figure
3). Recent studies have provided insights into the nature of tetraspanin “web”
interactions. These results allow us to speculate the nature of clustering of CoV early
entry factors.
We concluded that CD9-mediated clustering of receptors and TTSPs promoted
MERS-CoV and 229E-CoV early entry at the cell surface. Receptor/protease clustering
is necessary because CoV S proteins requiring simultaneous receptor engagement and
proteolysis at S2’ for fusion activation [65]. While the exact nature of TMPRSS2
interactions with these cleavage sites is unclear, due to lack of TMPRSS2 structural data,
the effective distance between TMPRSS2 and the DPP4/S complexes must be
constrained by the “reach” of the TMPRSS2 itself. Interestingly, TMPRSS2 is one of the
smallest characterized TTSPs which suggests a short range of proteolytic activity [106].
Thus the early virus entry process requires very closely-spaced DPP4 and TMPRSS2
proteins. Furthermore, it is likely that the successful activation of several adjacent S
proteins is needed for successful membrane fusion, as has been observed with influenza
HA [2] and HIV env [186, 187]. The tetraspanin-facilitated complexes of DPP4 and
TMPRSS2 likely permit rapid and simultaneous cleavage of multiple adjacent S proteins
that accounts for early entry.
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That an as-yet unidentified tetraspanin is a partner for one or more relevant
TTSPs is evidenced by the fact that CD9KO does not affect entry of MHV or SARSCoVs. Both of these CoVs can utilize TMPRSS2 for early entry. Based on our model, if
CD9 is necessary for TMPRSS2-rich clusters at the cell surface then CD9KO would
affect the entry of all of the tested CoVs. As it stands, the tetraspanin partners for
CEACAM, ACE2, and TMPRSS2 remain unidentified.
Our observations align with previous studies that describe tetraspanins holding
complexes of viral entry factors together at the cell surface (reviewed in[134]). To
determine which CoV entry factors interact with tetraspanins, our first experiments
involved the isolation and analysis of CHAPS detergent-resistant membranes. These
isolated membrane fractions contained a large diversity of tetraspanins and tetraspanin
partner proteins. Thus, these experiments assume a model of tetraspanin scaffolding
dependent on the existence of complex tetraspanin interactions that form tetraspaninenriched microdomains. These TEMs were thought to be large complexes of diverse
tetraspanins and tetraspanin-partner proteins forming stable structures at the cell surface.
These structures were thought to be formed largely due to favorable membrane
conditions, much like lipid rafts [188]. While this model of TEMs is based on the bulk of
the tetraspanin literature, we have come to appreciate that it is likely inaccurate because it
is based on an artefact of the solubilization of cellular membranes that leads to
condensation of tetraspanin clusters. A less heterogeneous model of tetraspanin
interactions has recently been described and may provide insight into how CoV entry
factors are held in close proximity.
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Recent studies using single-molecule resolution microscopy techniques refute the
old model that suggests TEMs are stable structures that contain a wide array of different
tetraspanins and transmembrane proteins [189, 190]. These data suggest individual
tetraspanins and their partner proteins exist as units at the cell surface and exhibit
Brownian diffusion through the plasma membrane. This complex roams the membrane
freely until it encounters other homotypic tetraspanins. The interaction with other
homotypic tetraspanins decreases both the diffusion rate and distance of the individual
tetraspanin unit and couples movement with the other homotypic tetraspanin(s). These
semi-stable interactions lead to the formation of clusters of homotypic tetraspanins and
their partner proteins that consist of 3-6 tetraspanin molecules (Figure 29).
Tetraspanin “web” interactions consist of these homotypic tetraspanin complexes
residing in close proximity with other homotypic tetraspanin complexes. This model
suggests that tetraspanins can not only promote close proximity of partner proteins, but
can also sequester partner proteins from each other. For example, the tetraspanin CD82
clusters major histocompatibility complex (MHC) proteins on antigen presenting cells,
which is necessary for efficient antigen presentation to T cells. However, the tetraspanin
CD37 can sequester MHC in these cells and prevent its interaction with CD82 [191].
The earlier models for TEMs suggested that tetraspanins facilitate partner protein
interactions based largely on clustering of tetraspanins in membrane raft domains.
However, the new model suggests that the interaction of partner proteins is less
dependent on the membrane composition and more dependent on tetraspanin-tetraspanin
interactions.
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While CHAPS detergent-resistant membranes are not representative of native
tetraspanin clusters at the cell surface, our results confirm that they remain a valuable tool
to analyze tetraspanin-partner protein interactions. CHAPS DRMs clearly purify
membranes that contain tetraspanins (Figure 12) and we have shown that this analysis
can be used to identify specific tetraspanin-partner protein interactions. For example,
DPP4 and APN are absent from CHAPS DRMs in CD9 depleted cells, but present in
CD9 replete cells (Figure 21). However, the proximity of different tetraspanin partner
proteins (such as DPP4 and TMPRSS2) at the cell surface cannot be determined with
certainty by these methods. Therefore, we conclude that analysis of protein complexes in
intact cells, by means such as PLA (Figure 22), is necessary to draw conclusions about
the clustering of these partner proteins at the cell surface.
Tetraspanins can form interactions with partner proteins in the endoplasmic
reticulum (ER) or at the cell surface. In the cases where tetraspanin-partner proteins
interactions are formed in the ER, tetraspanin expression can affect trafficking of the
partner protein to the cell surface. This is the case for CD81 and CD19 in B cells. When
CD81 was knocked out, CD19 accumulated in the ER but not at the cell surface [192].
Similar experiments determined that the tetraspanin UPIA forms interactions with
uroplakin proteins in the ER and is necessary for trafficking the uroplakins to the Golgi
and ultimately the cell surface [193].

We propose that the tetraspanin CD9 forms an

interaction with DPP4 at the cell surface, because we observed similar amounts of surface
DPP4 in the presence or absence of CD9 (Figures 8 and 20). Identifying the subcellular
location where DPP4 meets CD9 may facilitate the development of antiviral therapies
that may prevent this interaction.
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Potential Role for Cholesterol in CoV Early Entry.
Recent structural studies indicate that cholesterol is a determinant of tetraspanin
interactions with partner proteins [118]. The presence or absence of a single cholesterol
molecule in the TM domains of CD81 (Figure 4) determines both the tertiary structure of
the LEL and the ability to interact with a specific partner protein. Interestingly,
cholesterol is a known entry factor for MHV [116], SARS [113], 229E [114], and MERS
[171]. These studies emphasize the importance of cholesterol-rich lipid raft regions on
the cell surface for CoV endocytosis and/or fusion events. We propose that cholesterol
acts as a structural determinant of tetraspanin proteins and the absence of cholesterol
ablates tetraspanin interactions with CoV entry factors. While our initial experiments
failed to observe this phenomenon, we propose experiments in which CD9KO cells are
complemented with CD9 mutants incapable of binding to cholesterol. The mutations
needed to produce this mutant have already been characterized by Zimmerman et al. Our
hypothesis is that MERS early entry would not be restored in CD9KO cells
overexpressing the CD9 mutant. This result would provide a mechanistic understanding
of the role of cholesterol in CoV entry.
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Random Diffusion

Figure 29. Proposed model of tetraspanin-mediated clustering of MERS entry factors. The movement and clustering of tetraspanins and
partner proteins is depicted from a top down view. DPP4 (green) interacts with an individual CD9 tetraspanin protein (4 gray TM domains shown)
and exhibits Brownian diffusion through the membrane. Upon encountering one or several other CD9 molecules, the rate and distance of diffusion
of the CD9-DPP4 complex decreases significantly. Clustered, interacting CD9-DPP4 complexes exist in close proximity with complexes of an asyet unidentified tetraspanin (blue) that clusters TMPRSS2 (scissors). Thus, MERS entry factors are concentrated in complexes formed of
homotypic tetraspanin interactions and are held in close proximity to other homotypic tetraspanin complexes.
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CoV Evolution to Utilize Tetraspanin-associated Entry Factors.
The human CoVs use the transmembrane ectopeptidases ACE2 [102], APN [103],
and DPP4 [100] as host cell receptors. These receptors do not share any obvious
structural similarities, and while they do share ectopeptidase activities, these enzymatic
functions are dispensable for virus entry [100, 102, 103]. Localization in TEMs,
therefore, may be a shared feature that is relevant to the selection of these ectopeptidases
as CoV receptors.
We therefore find it likely that the CoVs evolved to use tetraspanin-associated
receptors so that, once bound to cells, the viruses are poised for cleavage by adjacent
proteases. It is possible, however, that the viruses adapted to use tetraspanin-associated
receptors for unknown reasons and then further evolved to utilize the abundant nearby
proteases for cleavage and priming. Regardless, the proteolytic environment created by
tetraspanin interactions is the preferred location for receptor-induced conformational
changes of S proteins, rapid proteolytic cleavage of the intermediate S conformations,
and possibly the subsequent refolding to postfusion forms, in spatial and temporal
patterns that foster efficient virus entry.
To determine if CoVs utilize different entry routes in cell culture and in mice, our
colleagues, Drs. Park and Li, have isolated and characterized a mouse adapted MERSCoV. A cell culture adapted HCoV-MERS was passaged 30 times in a permissive mouse
model and mutations were analyzed. Mutations occurred in the S1/S2 cleavage site, in
the S1 domain, and in the HR1 region of S2. These mutations increased the virulence of
the cell adapted strains and led to lethal infection. The majority of mutations observed at
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the S1/S2 region involved replacing serine residues with arginine. This would likely
make the S1/S2 a more efficient cleavage target for TTSPs and facilitate early entry. The
other mutations observed might lead to destabilized S trimers which facilitate cell-surface
entry in a similar manner as our trypsin destabilizations (Figure 11). We propose that
these mutations would increase the mouse adapted MERS-CoV reliance on CD9mediated early entry. Thus, utilization of CD9 entry routes may correlate with increased
MERS virulence.
Targeting Antiviral Peptides to Membranes.
Identifying and characterizing the entry factors and subcellular locations of CoV
early entry has provided us a unique opportunity to design antiviral therapies that
specifically target this route. As described in Chapter 1, HR2 peptides can block the
fusion reaction of type I viral fusion glycoproteins by binding to the HR1 region of the
extended intermediate and preventing complete zippering of the fusion domain (Figure
1). The efficacy of these peptides is limited by the relatively short duration of these
extended intermediate structures. Thus, soluble HR2 peptides need to be used in very
high concentrations to provide modest inhibition of infection (Figure 27) [194].
Our goal was to use our knowledge of the subcellular location of fusion to
increase the efficacy of antiviral HR2 peptides. Previous studies have shown that lipid
tagging HR2 peptides increases their efficacy, ostensibly by binding the HR2 to the
target-cell membrane [173, 195]. We know that tetraspanins are concentrated in
membrane regions that are rich in saturated fatty acids and cholesterol [196].
Interestingly, we observed that HR2 peptides tagged with these lipids were drastically
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more effective at blocking infection by early entering MHV-A59 and -JHM. We
concluded that palmitic acid and cholesterol tagged HR2s interact with the membranes
near tetraspanin complexes. These results also suggest that extended intermediate
structures form at or near tetraspanin complexes.
We also demonstrated the ability to predict which lipid tag would be effective
against a given CoV based on the likelihood of that virus entering early or late. Unlike
the MHV-A59 and -JHM strains, MHV-2 enters cells through an almost exclusively late
entry route. This MHV-2 virus was blocked by a tocopherol-tagged HR2 peptide that
was unable to efficiently block infection by the two early-entering MHVs. Because
tocopherol concentrates in the membranes of endosomes [175], these results confirm our
hypothesis that late entry occurs in the endosome. These results confirm that lipid-tagged
HR2 peptides can be effective tools for both blocking CoV infections and characterizing
which entry route a given CoV utilizes.
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